PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33424997-6	2020	Additionally, CUR, THC, and OHC significantly inhibited NF-kappaB activation and p38MAPK and ERK phosphorylation, while substantially upregulated the Nrf2 target gene expression (HO-1, NQO-1, GCLC, and GCLM).	tetrahydrocurcumin	19-22	glutamate-cysteine ligase, catalytic subunit	Mus musculus	192-196
33425220-0	2020	Novel PGC-1alpha/ATF5 Axis Partly Activates UPRmt and Mediates Cardioprotective Role of Tetrahydrocurcumin in Pathological Cardiac Hypertrophy.	tetrahydrocurcumin	88-106	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	6-16
33425220-0	2020	Novel PGC-1alpha/ATF5 Axis Partly Activates UPRmt and Mediates Cardioprotective Role of Tetrahydrocurcumin in Pathological Cardiac Hypertrophy.	tetrahydrocurcumin	88-106	activating transcription factor 5	Mus musculus	17-21
33425220-9	2020	Furthermore, PGC-1alpha knockdown blunted the UPRmt activation and the cardioprotective role of THC.	tetrahydrocurcumin	96-99	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	13-23
33425220-13	2020	The PGC-1alpha/ATF5 axis mediated the UPRmt activation and stress-resistance role of THC in vitro.	tetrahydrocurcumin	85-88	PPARG coactivator 1 alpha	Rattus norvegicus	4-14
33425220-13	2020	The PGC-1alpha/ATF5 axis mediated the UPRmt activation and stress-resistance role of THC in vitro.	tetrahydrocurcumin	85-88	activating transcription factor 5	Rattus norvegicus	15-19
33425220-14	2020	Collectively, the present study provides the first evidence that PGC-1 and ATF5 can form a signaling axis to partly activate UPRmt that mediates the cardioprotective role of THC in pathological cardiac hypertrophy.	tetrahydrocurcumin	174-177	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	65-70
33425220-14	2020	Collectively, the present study provides the first evidence that PGC-1 and ATF5 can form a signaling axis to partly activate UPRmt that mediates the cardioprotective role of THC in pathological cardiac hypertrophy.	tetrahydrocurcumin	174-177	activating transcription factor 5	Rattus norvegicus	75-79
33424997-5	2020	The results revealed that CUR, THC, and OHC dose-dependently inhibited the generation of NO and MCP-1 as well as the gene expression of MCP-1 and iNOS.	tetrahydrocurcumin	31-34	mast cell protease 1	Mus musculus	96-101
33424997-5	2020	The results revealed that CUR, THC, and OHC dose-dependently inhibited the generation of NO and MCP-1 as well as the gene expression of MCP-1 and iNOS.	tetrahydrocurcumin	31-34	mast cell protease 1	Mus musculus	136-141
33424997-6	2020	Additionally, CUR, THC, and OHC significantly inhibited NF-kappaB activation and p38MAPK and ERK phosphorylation, while substantially upregulated the Nrf2 target gene expression (HO-1, NQO-1, GCLC, and GCLM).	tetrahydrocurcumin	19-22	glutamate-cysteine ligase, modifier subunit	Mus musculus	202-206
33424997-5	2020	The results revealed that CUR, THC, and OHC dose-dependently inhibited the generation of NO and MCP-1 as well as the gene expression of MCP-1 and iNOS.	tetrahydrocurcumin	31-34	nitric oxide synthase 2, inducible	Mus musculus	146-150
33424997-8	2020	These results demonstrated that CUR, THC, and OHC exerted beneficial effect on LPS-stimulated inflammatory and oxidative responses, at least partially, through inhibiting the NF-kappaB and MAPKs pathways and activating Nrf2-regulated antioxidant gene expression.	tetrahydrocurcumin	37-40	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	175-184
33424997-6	2020	Additionally, CUR, THC, and OHC significantly inhibited NF-kappaB activation and p38MAPK and ERK phosphorylation, while substantially upregulated the Nrf2 target gene expression (HO-1, NQO-1, GCLC, and GCLM).	tetrahydrocurcumin	19-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	56-65
33424997-8	2020	These results demonstrated that CUR, THC, and OHC exerted beneficial effect on LPS-stimulated inflammatory and oxidative responses, at least partially, through inhibiting the NF-kappaB and MAPKs pathways and activating Nrf2-regulated antioxidant gene expression.	tetrahydrocurcumin	37-40	nuclear factor, erythroid derived 2, like 2	Mus musculus	219-223
33424997-6	2020	Additionally, CUR, THC, and OHC significantly inhibited NF-kappaB activation and p38MAPK and ERK phosphorylation, while substantially upregulated the Nrf2 target gene expression (HO-1, NQO-1, GCLC, and GCLM).	tetrahydrocurcumin	19-22	mitogen-activated protein kinase 14	Mus musculus	81-88
33424997-6	2020	Additionally, CUR, THC, and OHC significantly inhibited NF-kappaB activation and p38MAPK and ERK phosphorylation, while substantially upregulated the Nrf2 target gene expression (HO-1, NQO-1, GCLC, and GCLM).	tetrahydrocurcumin	19-22	mitogen-activated protein kinase 1	Mus musculus	93-96
32767918-0	2021	Comparative Inhibitory Efficacy on the iNOS/NO System of Curcumin- and Tetrahydrocurcumin-Self-Microemulsifying Liquid Formulation in Chronic Gastric Ulcer Model.	tetrahydrocurcumin	71-89	nitric oxide synthase 2	Rattus norvegicus	39-43
33424997-6	2020	Additionally, CUR, THC, and OHC significantly inhibited NF-kappaB activation and p38MAPK and ERK phosphorylation, while substantially upregulated the Nrf2 target gene expression (HO-1, NQO-1, GCLC, and GCLM).	tetrahydrocurcumin	19-22	nuclear factor, erythroid derived 2, like 2	Mus musculus	150-154
33424997-6	2020	Additionally, CUR, THC, and OHC significantly inhibited NF-kappaB activation and p38MAPK and ERK phosphorylation, while substantially upregulated the Nrf2 target gene expression (HO-1, NQO-1, GCLC, and GCLM).	tetrahydrocurcumin	19-22	heme oxygenase 1	Mus musculus	179-183
33424997-6	2020	Additionally, CUR, THC, and OHC significantly inhibited NF-kappaB activation and p38MAPK and ERK phosphorylation, while substantially upregulated the Nrf2 target gene expression (HO-1, NQO-1, GCLC, and GCLM).	tetrahydrocurcumin	19-22	NAD(P)H dehydrogenase, quinone 1	Mus musculus	185-190
32573860-0	2020	Tetrahydrocurcumin mitigates acute hypobaric hypoxia-induced cerebral oedema and inflammation through the NF-kappaB/VEGF/MMP-9 pathway.	tetrahydrocurcumin	0-18	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	106-115
32573860-0	2020	Tetrahydrocurcumin mitigates acute hypobaric hypoxia-induced cerebral oedema and inflammation through the NF-kappaB/VEGF/MMP-9 pathway.	tetrahydrocurcumin	0-18	vascular endothelial growth factor A	Mus musculus	116-120
32573860-0	2020	Tetrahydrocurcumin mitigates acute hypobaric hypoxia-induced cerebral oedema and inflammation through the NF-kappaB/VEGF/MMP-9 pathway.	tetrahydrocurcumin	0-18	matrix metallopeptidase 9	Mus musculus	121-126
32573860-3	2020	Our results revealed that prophylactic administration of THC (40 mg/kg) for 3 days significantly alleviated the increase in brain water content (BWC), interleukin-1beta (IL-1beta) and TNF-alpha levels caused by acute hypobaric hypoxia (AHH).	tetrahydrocurcumin	57-60	interleukin 1 beta	Mus musculus	151-168
32573860-3	2020	Our results revealed that prophylactic administration of THC (40 mg/kg) for 3 days significantly alleviated the increase in brain water content (BWC), interleukin-1beta (IL-1beta) and TNF-alpha levels caused by acute hypobaric hypoxia (AHH).	tetrahydrocurcumin	57-60	interleukin 1 alpha	Mus musculus	170-178
32573860-3	2020	Our results revealed that prophylactic administration of THC (40 mg/kg) for 3 days significantly alleviated the increase in brain water content (BWC), interleukin-1beta (IL-1beta) and TNF-alpha levels caused by acute hypobaric hypoxia (AHH).	tetrahydrocurcumin	57-60	tumor necrosis factor	Mus musculus	184-193
32573860-7	2020	Furthermore, THC administration remarkably downregulated VEGF, matrix metallopeptidase-9 (MMP-9), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) expression, both in vivo and in vitro.	tetrahydrocurcumin	13-16	vascular endothelial growth factor A	Mus musculus	57-61
32573860-7	2020	Furthermore, THC administration remarkably downregulated VEGF, matrix metallopeptidase-9 (MMP-9), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) expression, both in vivo and in vitro.	tetrahydrocurcumin	13-16	matrix metallopeptidase 9	Mus musculus	63-88
32573860-7	2020	Furthermore, THC administration remarkably downregulated VEGF, matrix metallopeptidase-9 (MMP-9), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) expression, both in vivo and in vitro.	tetrahydrocurcumin	13-16	matrix metallopeptidase 9	Mus musculus	90-95
32573860-7	2020	Furthermore, THC administration remarkably downregulated VEGF, matrix metallopeptidase-9 (MMP-9), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) expression, both in vivo and in vitro.	tetrahydrocurcumin	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	166-175
32573860-8	2020	Our data highlight the potential prophylactic activity of THC in HACE, it effectively mitigates AHH-induced cerebral oedema and inflammation is associated with the inhibition of the NF-kappaB/ VEGF/MMP-9 pathways.	tetrahydrocurcumin	58-61	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	182-191
32573860-8	2020	Our data highlight the potential prophylactic activity of THC in HACE, it effectively mitigates AHH-induced cerebral oedema and inflammation is associated with the inhibition of the NF-kappaB/ VEGF/MMP-9 pathways.	tetrahydrocurcumin	58-61	vascular endothelial growth factor A	Mus musculus	193-197
32573860-8	2020	Our data highlight the potential prophylactic activity of THC in HACE, it effectively mitigates AHH-induced cerebral oedema and inflammation is associated with the inhibition of the NF-kappaB/ VEGF/MMP-9 pathways.	tetrahydrocurcumin	58-61	matrix metallopeptidase 9	Mus musculus	198-203
32531320-0	2020	Tetrahydrocurcumin ameliorates diabetes profiles of db/db mice by altering the composition of gut microbiota and up-regulating the expression of GLP-1 in the pancreas.	tetrahydrocurcumin	0-18	glucagon	Mus musculus	145-150
32531320-4	2020	In the research, we investigated whether THC could improve diabetes by regulating the gut microbiota and the expression of pancreatic glucagon-like peptide-1 (GLP-1) in the db/db mice.	tetrahydrocurcumin	41-44	glucagon	Mus musculus	134-157
32531320-4	2020	In the research, we investigated whether THC could improve diabetes by regulating the gut microbiota and the expression of pancreatic glucagon-like peptide-1 (GLP-1) in the db/db mice.	tetrahydrocurcumin	41-44	glucagon	Mus musculus	159-164
32531320-7	2020	Compared to the diabetic group, THC treatment decreased significantly blood glucose, increased the secretion of insulin and the expression of GLP-1 in the pancreas.	tetrahydrocurcumin	32-35	glucagon	Mus musculus	142-147
32531320-11	2020	Altogether, these results demonstrated that THC might have a direct regulatory effect on gut microflora, which indirectly decrease the FBG levels by modulating GLP-1 expression in the pancreas.	tetrahydrocurcumin	44-47	glucagon	Mus musculus	160-165
32767918-5	2021	OBJECTIVE: This study aimed to evaluate and compare antiulcer efficacy of curcumin- and THC-SMEDDS through inhibition of the iNOS/NO system in rat model.	tetrahydrocurcumin	88-91	nitric oxide synthase 2	Rattus norvegicus	125-129
32767918-8	2021	SMEDDS used in the study significantly increased the inhibitory efficacy of THC on iNOS/NO production and iNOS mRNA expression into a comparable inhibitory potency to that of curcumin.	tetrahydrocurcumin	76-79	nitric oxide synthase 2	Rattus norvegicus	83-87
30900133-6	2019	It was found that THC exhibited equivalent gp120-CD4 binding inhibitory activity as compared with curcumin due to its stable hydrophobic interactions with residues Asp368 and Trp427 deeper in the Phe43 cavity of CD4 receptor.	tetrahydrocurcumin	18-21	CD4 molecule	Homo sapiens	49-52
32923007-0	2020	Solid and liquid state characterization of tetrahydrocurcumin using XRPD, FT-IR, DSC, TGA, LC-MS, GC-MS, and NMR and its biological activities.	tetrahydrocurcumin	43-61	desmocollin 3	Homo sapiens	81-84
32923007-0	2020	Solid and liquid state characterization of tetrahydrocurcumin using XRPD, FT-IR, DSC, TGA, LC-MS, GC-MS, and NMR and its biological activities.	tetrahydrocurcumin	43-61	T-box transcription factor 1	Homo sapiens	86-89
32923007-7	2020	THC was thermally stable up to 335.55  C. THC exhibited more suppression of cytokines (TNF-alpha, IL-1beta, and MIP-1alpha) than CUR in a concentration-dependent manner in mouse splenocytes, while NK-cell and phagocytosis activity was increased in macrophages.	tetrahydrocurcumin	0-3	tumor necrosis factor	Mus musculus	87-96
32923007-7	2020	THC was thermally stable up to 335.55  C. THC exhibited more suppression of cytokines (TNF-alpha, IL-1beta, and MIP-1alpha) than CUR in a concentration-dependent manner in mouse splenocytes, while NK-cell and phagocytosis activity was increased in macrophages.	tetrahydrocurcumin	0-3	chemokine (C-C motif) ligand 3	Mus musculus	112-122
32923007-7	2020	THC was thermally stable up to 335.55  C. THC exhibited more suppression of cytokines (TNF-alpha, IL-1beta, and MIP-1alpha) than CUR in a concentration-dependent manner in mouse splenocytes, while NK-cell and phagocytosis activity was increased in macrophages.	tetrahydrocurcumin	42-45	tumor necrosis factor	Mus musculus	87-96
32923007-7	2020	THC was thermally stable up to 335.55  C. THC exhibited more suppression of cytokines (TNF-alpha, IL-1beta, and MIP-1alpha) than CUR in a concentration-dependent manner in mouse splenocytes, while NK-cell and phagocytosis activity was increased in macrophages.	tetrahydrocurcumin	42-45	interleukin 1 alpha	Mus musculus	98-106
32923007-7	2020	THC was thermally stable up to 335.55  C. THC exhibited more suppression of cytokines (TNF-alpha, IL-1beta, and MIP-1alpha) than CUR in a concentration-dependent manner in mouse splenocytes, while NK-cell and phagocytosis activity was increased in macrophages.	tetrahydrocurcumin	42-45	chemokine (C-C motif) ligand 3	Mus musculus	112-122
32923007-8	2020	THC showed a significant reduction of free radicals (LPO) along with improved antioxidant enzymes (SOD and catalase) and increased free radical scavenging activity against ABTS+ radicals in HepG2 cells.	tetrahydrocurcumin	0-3	superoxide dismutase 1	Homo sapiens	99-115
31602247-0	2019	Tetrahydrocurcumin protects against spinal cord injury and inhibits the oxidative stress response by regulating FOXO4 in model rats.	tetrahydrocurcumin	0-18	forkhead box O4	Rattus norvegicus	112-117
31602247-4	2019	Furthermore, oxidative stress and apoptosis (caspase-3 activity and B-cell lymphoma 2-associated X protein levels) were also suppressed in SCI rats treated with tetrahydrocurcumin.	tetrahydrocurcumin	161-179	caspase 3	Rattus norvegicus	45-54
31602247-5	2019	Tetrahydrocurcumin effectively decreased the gene expression of matrix metalloproteinase-3 and -13, as well as cyclooxygenase-2, promoted the phosphorylation of Akt and enhanced the protein expression of forkhead box (FOX)O4 in SCI rats.	tetrahydrocurcumin	0-18	matrix metallopeptidase 3	Rattus norvegicus	64-98
31602247-5	2019	Tetrahydrocurcumin effectively decreased the gene expression of matrix metalloproteinase-3 and -13, as well as cyclooxygenase-2, promoted the phosphorylation of Akt and enhanced the protein expression of forkhead box (FOX)O4 in SCI rats.	tetrahydrocurcumin	0-18	AKT serine/threonine kinase 1	Rattus norvegicus	161-164
31602247-6	2019	The present study delineates that tetrahydrocurcumin protects against SCI and inhibits the oxidative stress response by regulating the FOXO4 in SCI model rats.	tetrahydrocurcumin	34-52	forkhead box O4	Rattus norvegicus	135-140
32784298-9	2020	Importantly, compared to the monotherapy groups (THC or DEX only), the combination of THC and DEX showed a significantly reduced nasal rubbing frequency, lower mucus hyperproduction, lower Th2 and Th17 cell numbers as well as lower related cytokine levels (IL-4, IL-5, and IL-17A).	tetrahydrocurcumin	86-89	interleukin 4	Mus musculus	257-261
32784298-9	2020	Importantly, compared to the monotherapy groups (THC or DEX only), the combination of THC and DEX showed a significantly reduced nasal rubbing frequency, lower mucus hyperproduction, lower Th2 and Th17 cell numbers as well as lower related cytokine levels (IL-4, IL-5, and IL-17A).	tetrahydrocurcumin	86-89	interleukin 5	Mus musculus	263-267
32784298-9	2020	Importantly, compared to the monotherapy groups (THC or DEX only), the combination of THC and DEX showed a significantly reduced nasal rubbing frequency, lower mucus hyperproduction, lower Th2 and Th17 cell numbers as well as lower related cytokine levels (IL-4, IL-5, and IL-17A).	tetrahydrocurcumin	86-89	interleukin 17A	Mus musculus	273-279
31905820-9	2019	Western blot analysis indicated that the phosphorylation of mitogen-activated protein kinases including c-Jun N-terminal kinase, extracellular signal-related kinases 1/2, and p38 by glutamate was significantly diminished by treatment with THC.	tetrahydrocurcumin	239-242	mitogen-activated protein kinase 14	Mus musculus	175-178
31030375-10	2019	Curcumin or THC complexes in HP-CDs with improved bioavailability also induced anti-oxidant activity (SOD1, CAT1, and HMOX1) in higher levels in the ocular epithelial cells and showed oxidative protection effects in rabbit cornea tissues that will boost up their application in ocular medicine.	tetrahydrocurcumin	12-15	superoxide dismutase [Cu-Zn]	Oryctolagus cuniculus	102-106
31030375-10	2019	Curcumin or THC complexes in HP-CDs with improved bioavailability also induced anti-oxidant activity (SOD1, CAT1, and HMOX1) in higher levels in the ocular epithelial cells and showed oxidative protection effects in rabbit cornea tissues that will boost up their application in ocular medicine.	tetrahydrocurcumin	12-15	heme oxygenase 1	Oryctolagus cuniculus	118-123
30900133-5	2019	To address this issue, tetrahydrocurcumin (THC), a colorless derivative of curcumin, was subjected to in silico screening (molecular docking and dynamics simulation studies) using homology model of gp120-CD4 binding.	tetrahydrocurcumin	23-41	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	198-203
30900133-5	2019	To address this issue, tetrahydrocurcumin (THC), a colorless derivative of curcumin, was subjected to in silico screening (molecular docking and dynamics simulation studies) using homology model of gp120-CD4 binding.	tetrahydrocurcumin	23-41	CD4 molecule	Homo sapiens	204-207
30900133-5	2019	To address this issue, tetrahydrocurcumin (THC), a colorless derivative of curcumin, was subjected to in silico screening (molecular docking and dynamics simulation studies) using homology model of gp120-CD4 binding.	tetrahydrocurcumin	43-46	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	198-203
30900133-5	2019	To address this issue, tetrahydrocurcumin (THC), a colorless derivative of curcumin, was subjected to in silico screening (molecular docking and dynamics simulation studies) using homology model of gp120-CD4 binding.	tetrahydrocurcumin	43-46	CD4 molecule	Homo sapiens	204-207
30900133-6	2019	It was found that THC exhibited equivalent gp120-CD4 binding inhibitory activity as compared with curcumin due to its stable hydrophobic interactions with residues Asp368 and Trp427 deeper in the Phe43 cavity of CD4 receptor.	tetrahydrocurcumin	18-21	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	43-48
30900133-6	2019	It was found that THC exhibited equivalent gp120-CD4 binding inhibitory activity as compared with curcumin due to its stable hydrophobic interactions with residues Asp368 and Trp427 deeper in the Phe43 cavity of CD4 receptor.	tetrahydrocurcumin	18-21	CD4 molecule	Homo sapiens	212-224
30816509-5	2019	Curcumin sulfate was transported by all three OATPs, although to a much lesser extent, while uptake of tetrahydrocurcumin was the highest but only via OATP1B1 and OATP1B3.	tetrahydrocurcumin	103-121	solute carrier organic anion transporter family member 1B3	Homo sapiens	163-170
31210844-0	2019	Tetrahydrocurcumin Ameliorates Diabetic Cardiomyopathy by Attenuating High Glucose-Induced Oxidative Stress and Fibrosis via Activating the SIRT1 Pathway.	tetrahydrocurcumin	0-18	sirtuin 1	Mus musculus	140-145
31210844-5	2019	Mechanically, THC administration remarkably increased the expression of the SIRT1 signaling pathway both in vitro and in vivo, further evidenced by decreased downstream molecule Ac-SOD2 and enhanced deacetylated production SOD2, which finally strengthened antioxidative stress capacity proven by repaired activities of SOD and GSH-Px and reduced MDA production.	tetrahydrocurcumin	14-17	sirtuin 1	Mus musculus	76-81
31210844-5	2019	Mechanically, THC administration remarkably increased the expression of the SIRT1 signaling pathway both in vitro and in vivo, further evidenced by decreased downstream molecule Ac-SOD2 and enhanced deacetylated production SOD2, which finally strengthened antioxidative stress capacity proven by repaired activities of SOD and GSH-Px and reduced MDA production.	tetrahydrocurcumin	14-17	superoxide dismutase 2, mitochondrial	Mus musculus	181-185
31210844-5	2019	Mechanically, THC administration remarkably increased the expression of the SIRT1 signaling pathway both in vitro and in vivo, further evidenced by decreased downstream molecule Ac-SOD2 and enhanced deacetylated production SOD2, which finally strengthened antioxidative stress capacity proven by repaired activities of SOD and GSH-Px and reduced MDA production.	tetrahydrocurcumin	14-17	superoxide dismutase 2, mitochondrial	Mus musculus	223-227
31210844-6	2019	Additionally, THC treatment accomplished its antifibrotic effect by depressing the ROS-induced TGFbeta1/Smad3 signaling pathway followed by reduced expression of cardiac fibrotic markers alpha-SMA, collagen I, and collagen III.	tetrahydrocurcumin	14-17	transforming growth factor, beta 1	Mus musculus	95-103
31210844-6	2019	Additionally, THC treatment accomplished its antifibrotic effect by depressing the ROS-induced TGFbeta1/Smad3 signaling pathway followed by reduced expression of cardiac fibrotic markers alpha-SMA, collagen I, and collagen III.	tetrahydrocurcumin	14-17	SMAD family member 3	Mus musculus	104-109
31210844-6	2019	Additionally, THC treatment accomplished its antifibrotic effect by depressing the ROS-induced TGFbeta1/Smad3 signaling pathway followed by reduced expression of cardiac fibrotic markers alpha-SMA, collagen I, and collagen III.	tetrahydrocurcumin	14-17	actin alpha 2, smooth muscle, aorta	Mus musculus	187-196
31210844-7	2019	Collectively, these finds demonstrated the therapeutic potential of THC treatment to alleviate DCM mainly by attenuating hyperglycemia-induced oxidative stress and fibrosis via activating the SIRT1 pathway.	tetrahydrocurcumin	68-71	sirtuin 1	Mus musculus	192-197
30816509-7	2019	The increased mRNA levels of OATP1B1 in wild-type human breast cancer ZR-75-1 cells compared with OATP1B1 knockdown cells was associated with a higher initial uptake of curcumin and tetrahydrocurcumin leading to decreased IC50 values.	tetrahydrocurcumin	182-200	solute carrier organic anion transporter family member 1B1	Homo sapiens	29-36
30816509-7	2019	The increased mRNA levels of OATP1B1 in wild-type human breast cancer ZR-75-1 cells compared with OATP1B1 knockdown cells was associated with a higher initial uptake of curcumin and tetrahydrocurcumin leading to decreased IC50 values.	tetrahydrocurcumin	182-200	solute carrier organic anion transporter family member 1B1	Homo sapiens	98-105
30137697-0	2018	Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice.	tetrahydrocurcumin	0-18	heart and neural crest derivatives expressed 2	Mus musculus	108-111
30423402-0	2019	Tetrahydrocurcumin and octahydrocurcumin, the primary and final hydrogenated metabolites of curcumin, possess superior hepatic-protective effect against acetaminophen-induced liver injury: Role of CYP2E1 and Keap1-Nrf2 pathway.	tetrahydrocurcumin	0-18	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	197-203
30423402-0	2019	Tetrahydrocurcumin and octahydrocurcumin, the primary and final hydrogenated metabolites of curcumin, possess superior hepatic-protective effect against acetaminophen-induced liver injury: Role of CYP2E1 and Keap1-Nrf2 pathway.	tetrahydrocurcumin	0-18	kelch like ECH associated protein 1	Homo sapiens	208-213
30423402-0	2019	Tetrahydrocurcumin and octahydrocurcumin, the primary and final hydrogenated metabolites of curcumin, possess superior hepatic-protective effect against acetaminophen-induced liver injury: Role of CYP2E1 and Keap1-Nrf2 pathway.	tetrahydrocurcumin	0-18	NFE2 like bZIP transcription factor 2	Homo sapiens	214-218
30423402-4	2019	Our results showed that OHC and THC dose-dependently enhanced liver function (ALT and AST levels) and alleviated histopathological deterioration.	tetrahydrocurcumin	32-35	solute carrier family 17 member 5	Homo sapiens	86-89
30423402-6	2019	In addition, OHC and THC markedly suppressed the activity and expressions of CYP2E1, and bound to the active sites of CYP2E1.	tetrahydrocurcumin	21-24	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	77-83
30423402-6	2019	In addition, OHC and THC markedly suppressed the activity and expressions of CYP2E1, and bound to the active sites of CYP2E1.	tetrahydrocurcumin	21-24	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	118-124
30423402-9	2019	In conclusion, OHC and THC possess favorable hepato-protective effect through restoring antioxidant status, inhibiting CYP2E1 and activating Keap1-Nrf2 pathway, which might represent promising antioxidants for the treatment of APAP-induced hepatotoxicity.	tetrahydrocurcumin	23-26	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	119-125
30423402-9	2019	In conclusion, OHC and THC possess favorable hepato-protective effect through restoring antioxidant status, inhibiting CYP2E1 and activating Keap1-Nrf2 pathway, which might represent promising antioxidants for the treatment of APAP-induced hepatotoxicity.	tetrahydrocurcumin	23-26	kelch like ECH associated protein 1	Homo sapiens	141-146
30423402-9	2019	In conclusion, OHC and THC possess favorable hepato-protective effect through restoring antioxidant status, inhibiting CYP2E1 and activating Keap1-Nrf2 pathway, which might represent promising antioxidants for the treatment of APAP-induced hepatotoxicity.	tetrahydrocurcumin	23-26	NFE2 like bZIP transcription factor 2	Homo sapiens	147-151
30137697-0	2018	Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice.	tetrahydrocurcumin	0-18	interleukin 4 receptor, alpha	Mus musculus	141-151
30137697-0	2018	Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice.	tetrahydrocurcumin	0-18	Janus kinase 1	Mus musculus	152-156
30137697-0	2018	Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice.	tetrahydrocurcumin	0-18	signal transducer and activator of transcription 6	Mus musculus	157-162
30137697-0	2018	Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice.	tetrahydrocurcumin	0-18	jagged 1	Mus musculus	167-174
30137697-0	2018	Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice.	tetrahydrocurcumin	0-18	jagged 2	Mus musculus	175-182
30137697-0	2018	Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice.	tetrahydrocurcumin	0-18	notch 1	Mus musculus	184-190
30137697-0	2018	Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice.	tetrahydrocurcumin	0-18	notch 2	Mus musculus	191-197
30137697-8	2018	RESULTS: Both THC and Cur had beneficial effects on asthmatic mice with regard to nasal symptoms, pathological changes (eosinophils and mucus hyper-production), oxidative stress (malondialdehyde), cytokine production (IL-13), Th17 and cytotoxic T cell subsets, and Th2 signalling pathway (IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2-Notch1/Notch2 axis) activity.	tetrahydrocurcumin	14-17	heart and neural crest derivatives expressed 2	Mus musculus	265-268
30137697-8	2018	RESULTS: Both THC and Cur had beneficial effects on asthmatic mice with regard to nasal symptoms, pathological changes (eosinophils and mucus hyper-production), oxidative stress (malondialdehyde), cytokine production (IL-13), Th17 and cytotoxic T cell subsets, and Th2 signalling pathway (IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2-Notch1/Notch2 axis) activity.	tetrahydrocurcumin	14-17	interleukin 4 receptor, alpha	Mus musculus	289-299
30137697-8	2018	RESULTS: Both THC and Cur had beneficial effects on asthmatic mice with regard to nasal symptoms, pathological changes (eosinophils and mucus hyper-production), oxidative stress (malondialdehyde), cytokine production (IL-13), Th17 and cytotoxic T cell subsets, and Th2 signalling pathway (IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2-Notch1/Notch2 axis) activity.	tetrahydrocurcumin	14-17	Janus kinase 1	Mus musculus	300-304
30137697-8	2018	RESULTS: Both THC and Cur had beneficial effects on asthmatic mice with regard to nasal symptoms, pathological changes (eosinophils and mucus hyper-production), oxidative stress (malondialdehyde), cytokine production (IL-13), Th17 and cytotoxic T cell subsets, and Th2 signalling pathway (IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2-Notch1/Notch2 axis) activity.	tetrahydrocurcumin	14-17	signal transducer and activator of transcription 6	Mus musculus	305-310
30137697-8	2018	RESULTS: Both THC and Cur had beneficial effects on asthmatic mice with regard to nasal symptoms, pathological changes (eosinophils and mucus hyper-production), oxidative stress (malondialdehyde), cytokine production (IL-13), Th17 and cytotoxic T cell subsets, and Th2 signalling pathway (IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2-Notch1/Notch2 axis) activity.	tetrahydrocurcumin	14-17	jagged 1	Mus musculus	315-322
30137697-8	2018	RESULTS: Both THC and Cur had beneficial effects on asthmatic mice with regard to nasal symptoms, pathological changes (eosinophils and mucus hyper-production), oxidative stress (malondialdehyde), cytokine production (IL-13), Th17 and cytotoxic T cell subsets, and Th2 signalling pathway (IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2-Notch1/Notch2 axis) activity.	tetrahydrocurcumin	14-17	jagged 2	Mus musculus	323-330
30137697-8	2018	RESULTS: Both THC and Cur had beneficial effects on asthmatic mice with regard to nasal symptoms, pathological changes (eosinophils and mucus hyper-production), oxidative stress (malondialdehyde), cytokine production (IL-13), Th17 and cytotoxic T cell subsets, and Th2 signalling pathway (IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2-Notch1/Notch2 axis) activity.	tetrahydrocurcumin	14-17	notch 1	Mus musculus	331-337
30137697-8	2018	RESULTS: Both THC and Cur had beneficial effects on asthmatic mice with regard to nasal symptoms, pathological changes (eosinophils and mucus hyper-production), oxidative stress (malondialdehyde), cytokine production (IL-13), Th17 and cytotoxic T cell subsets, and Th2 signalling pathway (IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2-Notch1/Notch2 axis) activity.	tetrahydrocurcumin	14-17	notch 2	Mus musculus	338-344
30137697-9	2018	THC was more effective than Cur in suppressing tissue eosinophilia, mucus production, and IL-4Ralpha/Jak1/STAT6 pathway activity.	tetrahydrocurcumin	0-3	interleukin 4 receptor, alpha	Mus musculus	90-100
30137697-9	2018	THC was more effective than Cur in suppressing tissue eosinophilia, mucus production, and IL-4Ralpha/Jak1/STAT6 pathway activity.	tetrahydrocurcumin	0-3	Janus kinase 1	Mus musculus	101-105
30137697-9	2018	THC was more effective than Cur in suppressing tissue eosinophilia, mucus production, and IL-4Ralpha/Jak1/STAT6 pathway activity.	tetrahydrocurcumin	0-3	signal transducer and activator of transcription 6	Mus musculus	106-111
30137697-10	2018	Furthermore, only THC inhibited peripheral eosinophil levels, Th2 cytokines (IL-4 and IL-5), and Th2 cell subsets and enhanced an antioxidant enzyme (glutathione).	tetrahydrocurcumin	18-21	heart and neural crest derivatives expressed 2	Mus musculus	62-65
30137697-10	2018	Furthermore, only THC inhibited peripheral eosinophil levels, Th2 cytokines (IL-4 and IL-5), and Th2 cell subsets and enhanced an antioxidant enzyme (glutathione).	tetrahydrocurcumin	18-21	interleukin 4	Mus musculus	77-81
30137697-10	2018	Furthermore, only THC inhibited peripheral eosinophil levels, Th2 cytokines (IL-4 and IL-5), and Th2 cell subsets and enhanced an antioxidant enzyme (glutathione).	tetrahydrocurcumin	18-21	interleukin 5	Mus musculus	86-90
30137697-10	2018	Furthermore, only THC inhibited peripheral eosinophil levels, Th2 cytokines (IL-4 and IL-5), and Th2 cell subsets and enhanced an antioxidant enzyme (glutathione).	tetrahydrocurcumin	18-21	heart and neural crest derivatives expressed 2	Mus musculus	97-100
30137697-11	2018	CONCLUSION AND CLINICAL RELEVANCE: The above results demonstrated for the first time that THC was superior to Cur in modulating allergic asthmatic phenotypes, especially attenuating the Th2 response.	tetrahydrocurcumin	90-93	heart and neural crest derivatives expressed 2	Mus musculus	186-189
30401411-9	2018	The effect of apoptosis by THC in LLC-PK1 cells was determined by measuring the caspase-9, caspase-3, B-cell lymphoma-2 (Bcl-2), and Bcl-2-associated X protein levels using Western blotting analyses.	tetrahydrocurcumin	27-30	apoptosis regulator Bcl-2	Sus scrofa	133-138
30401411-13	2018	Apoptosis was significantly decreased, and Bcl-2 was elevated in the THC-treated group.	tetrahydrocurcumin	69-72	apoptosis regulator Bcl-2	Sus scrofa	43-48
30401410-13	2018	The streptozocin-treated INS-1 cell produced significantly higher levels of and B-cell lymphoma-2-associated X protein, caspase-3, and caspase-9 than INS-1 treated with THC.	tetrahydrocurcumin	169-172	insulin 1	Rattus norvegicus	25-30
30401411-14	2018	Bcl-2-associated X protein, caspase-3, and caspase-9 were decreased in the THC-treated group.	tetrahydrocurcumin	75-78	apoptosis regulator Bcl-2	Sus scrofa	0-5
30401411-9	2018	The effect of apoptosis by THC in LLC-PK1 cells was determined by measuring the caspase-9, caspase-3, B-cell lymphoma-2 (Bcl-2), and Bcl-2-associated X protein levels using Western blotting analyses.	tetrahydrocurcumin	27-30	caspase 9	Sus scrofa	80-89
30401411-9	2018	The effect of apoptosis by THC in LLC-PK1 cells was determined by measuring the caspase-9, caspase-3, B-cell lymphoma-2 (Bcl-2), and Bcl-2-associated X protein levels using Western blotting analyses.	tetrahydrocurcumin	27-30	caspase 3	Sus scrofa	91-119
30401411-14	2018	Bcl-2-associated X protein, caspase-3, and caspase-9 were decreased in the THC-treated group.	tetrahydrocurcumin	75-78	caspase 3	Sus scrofa	28-37
30401411-14	2018	Bcl-2-associated X protein, caspase-3, and caspase-9 were decreased in the THC-treated group.	tetrahydrocurcumin	75-78	caspase 9	Sus scrofa	43-52
30386242-5	2018	Moreover, THC and OHC treatments were more effective than CUR in selectively inhibiting the expression of cyclooxygenase 2 (COX-2) and suppressing nuclear factor-kappaB (NF-kappaB) pathways via transforming growth factor beta activated kinase-1 (TAK1) inactivation in the carrageenan-induced mouse paw edema model.	tetrahydrocurcumin	10-13	prostaglandin-endoperoxide synthase 2	Mus musculus	106-122
30386242-5	2018	Moreover, THC and OHC treatments were more effective than CUR in selectively inhibiting the expression of cyclooxygenase 2 (COX-2) and suppressing nuclear factor-kappaB (NF-kappaB) pathways via transforming growth factor beta activated kinase-1 (TAK1) inactivation in the carrageenan-induced mouse paw edema model.	tetrahydrocurcumin	10-13	prostaglandin-endoperoxide synthase 2	Mus musculus	124-129
30386242-5	2018	Moreover, THC and OHC treatments were more effective than CUR in selectively inhibiting the expression of cyclooxygenase 2 (COX-2) and suppressing nuclear factor-kappaB (NF-kappaB) pathways via transforming growth factor beta activated kinase-1 (TAK1) inactivation in the carrageenan-induced mouse paw edema model.	tetrahydrocurcumin	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-168
30386242-5	2018	Moreover, THC and OHC treatments were more effective than CUR in selectively inhibiting the expression of cyclooxygenase 2 (COX-2) and suppressing nuclear factor-kappaB (NF-kappaB) pathways via transforming growth factor beta activated kinase-1 (TAK1) inactivation in the carrageenan-induced mouse paw edema model.	tetrahydrocurcumin	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	170-179
30386242-5	2018	Moreover, THC and OHC treatments were more effective than CUR in selectively inhibiting the expression of cyclooxygenase 2 (COX-2) and suppressing nuclear factor-kappaB (NF-kappaB) pathways via transforming growth factor beta activated kinase-1 (TAK1) inactivation in the carrageenan-induced mouse paw edema model.	tetrahydrocurcumin	10-13	mitogen-activated protein kinase kinase kinase 7	Mus musculus	194-244
30386242-5	2018	Moreover, THC and OHC treatments were more effective than CUR in selectively inhibiting the expression of cyclooxygenase 2 (COX-2) and suppressing nuclear factor-kappaB (NF-kappaB) pathways via transforming growth factor beta activated kinase-1 (TAK1) inactivation in the carrageenan-induced mouse paw edema model.	tetrahydrocurcumin	10-13	mitogen-activated protein kinase kinase kinase 7	Mus musculus	246-250
29976400-0	2018	Tetrahydrocurcumin ameliorates free fatty acid-induced hepatic steatosis and improves insulin resistance in HepG2 cells.	tetrahydrocurcumin	0-18	insulin	Homo sapiens	86-93
29976400-4	2018	The results showed that THC treatment significantly decreased lipid accumulation in OA-treated HepG2 cells, possibly, by inhibiting the expression of the lipogenic proteins, sterol regulatory element-binding protein 1 (SREBP-1c), peroxisome proliferator-activated receptor gamma (PPARgamma), fatty acid synthase (FAS), and fatty acid-binding protein 4 (FABP4).	tetrahydrocurcumin	24-27	sterol regulatory element binding transcription factor 1	Homo sapiens	174-217
29976400-4	2018	The results showed that THC treatment significantly decreased lipid accumulation in OA-treated HepG2 cells, possibly, by inhibiting the expression of the lipogenic proteins, sterol regulatory element-binding protein 1 (SREBP-1c), peroxisome proliferator-activated receptor gamma (PPARgamma), fatty acid synthase (FAS), and fatty acid-binding protein 4 (FABP4).	tetrahydrocurcumin	24-27	sterol regulatory element binding transcription factor 1	Homo sapiens	219-227
29976400-4	2018	The results showed that THC treatment significantly decreased lipid accumulation in OA-treated HepG2 cells, possibly, by inhibiting the expression of the lipogenic proteins, sterol regulatory element-binding protein 1 (SREBP-1c), peroxisome proliferator-activated receptor gamma (PPARgamma), fatty acid synthase (FAS), and fatty acid-binding protein 4 (FABP4).	tetrahydrocurcumin	24-27	peroxisome proliferator activated receptor gamma	Homo sapiens	230-278
29976400-4	2018	The results showed that THC treatment significantly decreased lipid accumulation in OA-treated HepG2 cells, possibly, by inhibiting the expression of the lipogenic proteins, sterol regulatory element-binding protein 1 (SREBP-1c), peroxisome proliferator-activated receptor gamma (PPARgamma), fatty acid synthase (FAS), and fatty acid-binding protein 4 (FABP4).	tetrahydrocurcumin	24-27	peroxisome proliferator activated receptor gamma	Homo sapiens	280-289
29976400-4	2018	The results showed that THC treatment significantly decreased lipid accumulation in OA-treated HepG2 cells, possibly, by inhibiting the expression of the lipogenic proteins, sterol regulatory element-binding protein 1 (SREBP-1c), peroxisome proliferator-activated receptor gamma (PPARgamma), fatty acid synthase (FAS), and fatty acid-binding protein 4 (FABP4).	tetrahydrocurcumin	24-27	fatty acid synthase	Homo sapiens	292-311
29976400-4	2018	The results showed that THC treatment significantly decreased lipid accumulation in OA-treated HepG2 cells, possibly, by inhibiting the expression of the lipogenic proteins, sterol regulatory element-binding protein 1 (SREBP-1c), peroxisome proliferator-activated receptor gamma (PPARgamma), fatty acid synthase (FAS), and fatty acid-binding protein 4 (FABP4).	tetrahydrocurcumin	24-27	fatty acid synthase	Homo sapiens	313-316
29976400-4	2018	The results showed that THC treatment significantly decreased lipid accumulation in OA-treated HepG2 cells, possibly, by inhibiting the expression of the lipogenic proteins, sterol regulatory element-binding protein 1 (SREBP-1c), peroxisome proliferator-activated receptor gamma (PPARgamma), fatty acid synthase (FAS), and fatty acid-binding protein 4 (FABP4).	tetrahydrocurcumin	24-27	fatty acid binding protein 4	Homo sapiens	323-351
29976400-4	2018	The results showed that THC treatment significantly decreased lipid accumulation in OA-treated HepG2 cells, possibly, by inhibiting the expression of the lipogenic proteins, sterol regulatory element-binding protein 1 (SREBP-1c), peroxisome proliferator-activated receptor gamma (PPARgamma), fatty acid synthase (FAS), and fatty acid-binding protein 4 (FABP4).	tetrahydrocurcumin	24-27	fatty acid binding protein 4	Homo sapiens	353-358
29976400-5	2018	Moreover, THC attenuated OA-induced hepatic lipogenesis in an adenosine monophosphate-activated protein kinase (AMPK)-dependent manner, which was reversed by pretreatment with an AMPK inhibitor.	tetrahydrocurcumin	10-13	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	62-110
29976400-5	2018	Moreover, THC attenuated OA-induced hepatic lipogenesis in an adenosine monophosphate-activated protein kinase (AMPK)-dependent manner, which was reversed by pretreatment with an AMPK inhibitor.	tetrahydrocurcumin	10-13	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	112-116
29976400-5	2018	Moreover, THC attenuated OA-induced hepatic lipogenesis in an adenosine monophosphate-activated protein kinase (AMPK)-dependent manner, which was reversed by pretreatment with an AMPK inhibitor.	tetrahydrocurcumin	10-13	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	179-183
29976400-7	2018	Glucose uptake and insulin signaling impaired in HepG2 cells incubated with OA were abated by THC treatment, including phosphorylation of the insulin receptor substrate 1 (IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt and downstream signaling pathways, forkhead box protein O1 (FOXO1) and glycogen synthase kinase 3 beta (GSK3beta), which are involved in gluconeogenesis and glycogen synthesis, respectively.	tetrahydrocurcumin	94-97	insulin receptor substrate 1	Homo sapiens	142-170
29976400-7	2018	Glucose uptake and insulin signaling impaired in HepG2 cells incubated with OA were abated by THC treatment, including phosphorylation of the insulin receptor substrate 1 (IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt and downstream signaling pathways, forkhead box protein O1 (FOXO1) and glycogen synthase kinase 3 beta (GSK3beta), which are involved in gluconeogenesis and glycogen synthesis, respectively.	tetrahydrocurcumin	94-97	insulin receptor substrate 1	Homo sapiens	172-177
29976400-7	2018	Glucose uptake and insulin signaling impaired in HepG2 cells incubated with OA were abated by THC treatment, including phosphorylation of the insulin receptor substrate 1 (IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt and downstream signaling pathways, forkhead box protein O1 (FOXO1) and glycogen synthase kinase 3 beta (GSK3beta), which are involved in gluconeogenesis and glycogen synthesis, respectively.	tetrahydrocurcumin	94-97	AKT serine/threonine kinase 1	Homo sapiens	212-215
29976400-7	2018	Glucose uptake and insulin signaling impaired in HepG2 cells incubated with OA were abated by THC treatment, including phosphorylation of the insulin receptor substrate 1 (IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt and downstream signaling pathways, forkhead box protein O1 (FOXO1) and glycogen synthase kinase 3 beta (GSK3beta), which are involved in gluconeogenesis and glycogen synthesis, respectively.	tetrahydrocurcumin	94-97	forkhead box O1	Homo sapiens	251-274
29976400-7	2018	Glucose uptake and insulin signaling impaired in HepG2 cells incubated with OA were abated by THC treatment, including phosphorylation of the insulin receptor substrate 1 (IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt and downstream signaling pathways, forkhead box protein O1 (FOXO1) and glycogen synthase kinase 3 beta (GSK3beta), which are involved in gluconeogenesis and glycogen synthesis, respectively.	tetrahydrocurcumin	94-97	forkhead box O1	Homo sapiens	276-281
29976400-7	2018	Glucose uptake and insulin signaling impaired in HepG2 cells incubated with OA were abated by THC treatment, including phosphorylation of the insulin receptor substrate 1 (IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt and downstream signaling pathways, forkhead box protein O1 (FOXO1) and glycogen synthase kinase 3 beta (GSK3beta), which are involved in gluconeogenesis and glycogen synthesis, respectively.	tetrahydrocurcumin	94-97	glycogen synthase kinase 3 beta	Homo sapiens	287-318
29976400-7	2018	Glucose uptake and insulin signaling impaired in HepG2 cells incubated with OA were abated by THC treatment, including phosphorylation of the insulin receptor substrate 1 (IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt and downstream signaling pathways, forkhead box protein O1 (FOXO1) and glycogen synthase kinase 3 beta (GSK3beta), which are involved in gluconeogenesis and glycogen synthesis, respectively.	tetrahydrocurcumin	94-97	glycogen synthase kinase 3 beta	Homo sapiens	320-328
29207631-0	2017	Tetrahydrocurcumin induces mesenchymal-epithelial transition and suppresses angiogenesis by targeting HIF-1alpha and autophagy in human osteosarcoma.	tetrahydrocurcumin	0-18	hypoxia inducible factor 1 subunit alpha	Homo sapiens	102-112
29719770-9	2018	From our study, novel LMTK3 inhibitors tetrahydrocurcumin, curcumin 4,4"-diacetate, and demethoxycurcumin have been proposed with inhibition mechanism.	tetrahydrocurcumin	39-57	lemur tyrosine kinase 3	Homo sapiens	22-27
29436654-0	2018	Tetrahydrocurcumin-induced autophagy via suppression of PI3K/Akt/mTOR in non-small cell lung carcinoma cells.	tetrahydrocurcumin	0-18	AKT serine/threonine kinase 1	Homo sapiens	61-64
29436654-0	2018	Tetrahydrocurcumin-induced autophagy via suppression of PI3K/Akt/mTOR in non-small cell lung carcinoma cells.	tetrahydrocurcumin	0-18	mechanistic target of rapamycin kinase	Homo sapiens	65-69
29436654-7	2018	The RT-qPCR analysis revealed that THC treatment increased Beclin-1 expression level and compared with the control group (P<0.05).	tetrahydrocurcumin	35-38	beclin 1	Homo sapiens	59-67
29436654-8	2018	The light chain 3 (LC3)-II/LC3-I ratio was reduced in THC-treated cells when compared with the control group (P<0.05).	tetrahydrocurcumin	54-57	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	19-22
29436654-8	2018	The light chain 3 (LC3)-II/LC3-I ratio was reduced in THC-treated cells when compared with the control group (P<0.05).	tetrahydrocurcumin	54-57	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	27-30
29436654-11	2018	A promising method of enhancing the therapeutic efficacy of THC against NSCLC cells may include inducing autophagy via inhibition of the PI3K/Akt/mTOR signaling pathway.	tetrahydrocurcumin	60-63	AKT serine/threonine kinase 1	Homo sapiens	142-145
29436654-11	2018	A promising method of enhancing the therapeutic efficacy of THC against NSCLC cells may include inducing autophagy via inhibition of the PI3K/Akt/mTOR signaling pathway.	tetrahydrocurcumin	60-63	mechanistic target of rapamycin kinase	Homo sapiens	146-150
29492979-10	2018	CONCLUSIONS: Tetrahydrocurcumin can synergistically enhance the radiosensitivity of glioma cells by inhibiting the expressions of cyclin D1 and PCNA.	tetrahydrocurcumin	13-31	cyclin D1	Mus musculus	130-139
29492979-10	2018	CONCLUSIONS: Tetrahydrocurcumin can synergistically enhance the radiosensitivity of glioma cells by inhibiting the expressions of cyclin D1 and PCNA.	tetrahydrocurcumin	13-31	proliferating cell nuclear antigen	Mus musculus	144-148
28833102-5	2018	We hypothesized that THC may ameliorates Hcy-induced mitochondria remodeling in mouse brain endothelial cells (bEnd3) cells.	tetrahydrocurcumin	21-24	BEN domain containing 3	Mus musculus	111-116
28833102-6	2018	bEnd3 cells were exposed to Hcy treatment in the presence or absence of THC.	tetrahydrocurcumin	72-75	BEN domain containing 3	Mus musculus	0-5
28833102-15	2018	Pretreatment of bEnd3 with THC (15 muM) ameliorated Hcy-induced oxidative damage, mitochondrial fission/fusion, and mitophagy.	tetrahydrocurcumin	27-30	BEN domain containing 3	Mus musculus	16-21
29468071-10	2018	THC therapy restored levels of CuZn SOD and glutathione peroxidase.	tetrahydrocurcumin	0-3	superoxide dismutase 1	Rattus norvegicus	31-39
29023392-0	2017	Disposition, Metabolism and Histone Deacetylase and Acetyltransferase Inhibition Activity of Tetrahydrocurcumin and Other Curcuminoids.	tetrahydrocurcumin	93-111	histone deacetylase 9	Homo sapiens	28-47
28766664-7	2017	THC induced the apoptosis of H22 cells obviously by increasing the level of p53 and decreasing the level of murine double minute 2.	tetrahydrocurcumin	0-3	transformation related protein 53, pseudogene	Mus musculus	76-79
28766664-8	2017	THC also decreased the expression of Bcl-2 significantly and increased the expression of Bcl2-associated X, resulting in the release of cytochrome C. THC significantly activated and induced cleavage of caspase-3 and caspase-9 to induce the apoptosis of H22 cells.	tetrahydrocurcumin	0-3	B cell leukemia/lymphoma 2	Mus musculus	37-42
28766664-8	2017	THC also decreased the expression of Bcl-2 significantly and increased the expression of Bcl2-associated X, resulting in the release of cytochrome C. THC significantly activated and induced cleavage of caspase-3 and caspase-9 to induce the apoptosis of H22 cells.	tetrahydrocurcumin	0-3	B cell leukemia/lymphoma 2	Mus musculus	89-93
28766664-8	2017	THC also decreased the expression of Bcl-2 significantly and increased the expression of Bcl2-associated X, resulting in the release of cytochrome C. THC significantly activated and induced cleavage of caspase-3 and caspase-9 to induce the apoptosis of H22 cells.	tetrahydrocurcumin	0-3	caspase 3	Mus musculus	202-211
28766664-8	2017	THC also decreased the expression of Bcl-2 significantly and increased the expression of Bcl2-associated X, resulting in the release of cytochrome C. THC significantly activated and induced cleavage of caspase-3 and caspase-9 to induce the apoptosis of H22 cells.	tetrahydrocurcumin	0-3	caspase 9	Mus musculus	216-225
28766664-8	2017	THC also decreased the expression of Bcl-2 significantly and increased the expression of Bcl2-associated X, resulting in the release of cytochrome C. THC significantly activated and induced cleavage of caspase-3 and caspase-9 to induce the apoptosis of H22 cells.	tetrahydrocurcumin	150-153	B cell leukemia/lymphoma 2	Mus musculus	37-42
28766664-8	2017	THC also decreased the expression of Bcl-2 significantly and increased the expression of Bcl2-associated X, resulting in the release of cytochrome C. THC significantly activated and induced cleavage of caspase-3 and caspase-9 to induce the apoptosis of H22 cells.	tetrahydrocurcumin	150-153	B cell leukemia/lymphoma 2	Mus musculus	89-93
28766664-8	2017	THC also decreased the expression of Bcl-2 significantly and increased the expression of Bcl2-associated X, resulting in the release of cytochrome C. THC significantly activated and induced cleavage of caspase-3 and caspase-9 to induce the apoptosis of H22 cells.	tetrahydrocurcumin	150-153	caspase 3	Mus musculus	202-211
28766664-8	2017	THC also decreased the expression of Bcl-2 significantly and increased the expression of Bcl2-associated X, resulting in the release of cytochrome C. THC significantly activated and induced cleavage of caspase-3 and caspase-9 to induce the apoptosis of H22 cells.	tetrahydrocurcumin	150-153	caspase 9	Mus musculus	216-225
29207631-8	2017	Mechanistically, our study showed that HIF-1alpha had a pivotal role in the anti-metastatic effect of THC.	tetrahydrocurcumin	102-105	hypoxia inducible factor 1 subunit alpha	Homo sapiens	39-49
29207631-9	2017	Importantly, HIF-1alpha expression was downregulated by THC by inhibiting Akt/mTOR and p38 MAPK pathways.	tetrahydrocurcumin	56-59	hypoxia inducible factor 1 subunit alpha	Homo sapiens	13-23
29207631-9	2017	Importantly, HIF-1alpha expression was downregulated by THC by inhibiting Akt/mTOR and p38 MAPK pathways.	tetrahydrocurcumin	56-59	AKT serine/threonine kinase 1	Homo sapiens	74-77
29207631-9	2017	Importantly, HIF-1alpha expression was downregulated by THC by inhibiting Akt/mTOR and p38 MAPK pathways.	tetrahydrocurcumin	56-59	mechanistic target of rapamycin kinase	Homo sapiens	78-82
29207631-9	2017	Importantly, HIF-1alpha expression was downregulated by THC by inhibiting Akt/mTOR and p38 MAPK pathways.	tetrahydrocurcumin	56-59	mitogen-activated protein kinase 14	Homo sapiens	87-90
29207631-10	2017	Moreover, THC exhibited a remarkable inhibitory effect on HIF-1alpha expression and angiogenesis under hypoxic conditions.	tetrahydrocurcumin	10-13	hypoxia inducible factor 1 subunit alpha	Homo sapiens	58-68
29207631-11	2017	Furthermore, THC activated autophagy and induced MET and suppressed angiogenesis in a HIF-1alpha-related manner.	tetrahydrocurcumin	13-16	hypoxia inducible factor 1 subunit alpha	Homo sapiens	86-96
29207631-12	2017	Taken together, our findings suggest that THC suppresses metastasis and invasion and this may be associated with HIF-1alpha and autophagy, which would potentially provide therapeutic strategies for human osteosarcoma.	tetrahydrocurcumin	42-45	hypoxia inducible factor 1 subunit alpha	Homo sapiens	113-123
27748926-7	2016	THC induced a dose-dependent decrease in the phosphorylation of ERK and GRASP65.	tetrahydrocurcumin	0-3	mitogen-activated protein kinase 1	Mus musculus	64-67
29669346-10	2017	These results suggest that THC improves neurological outcome after TBI, possibly by activating the Nrf2 signaling pathway.	tetrahydrocurcumin	27-30	NFE2 like bZIP transcription factor 2	Rattus norvegicus	99-103
27713040-8	2016	An imbalance between endothelial nitric oxide synthase (eNOS) and inducible NOS (iNOS) expression in response to iron overload was normalized by THU, L1 or the combination treatment.	tetrahydrocurcumin	145-148	nitric oxide synthase 3, endothelial cell	Mus musculus	21-54
27713040-8	2016	An imbalance between endothelial nitric oxide synthase (eNOS) and inducible NOS (iNOS) expression in response to iron overload was normalized by THU, L1 or the combination treatment.	tetrahydrocurcumin	145-148	nitric oxide synthase 2, inducible	Mus musculus	66-79
27713040-8	2016	An imbalance between endothelial nitric oxide synthase (eNOS) and inducible NOS (iNOS) expression in response to iron overload was normalized by THU, L1 or the combination treatment.	tetrahydrocurcumin	145-148	nitric oxide synthase 2, inducible	Mus musculus	81-85
27916377-0	2016	Tetrahydrocurcumin provides neuroprotection in rats after traumatic brain injury: autophagy and the PI3K/AKT pathways as a potential mechanism.	tetrahydrocurcumin	0-18	AKT serine/threonine kinase 1	Rattus norvegicus	105-108
27916377-8	2016	RESULTS: Our data indicated that administration of tetrahydrocurcumin alleviated brain edema, attenuated TBI-induced neuron cell death, decreased the degree of apoptosis and improved neurobehavioral function, which were accompanied by enhanced autophagy and phospho-AKT after TBI.	tetrahydrocurcumin	51-69	AKT serine/threonine kinase 1	Rattus norvegicus	266-269
27916377-10	2016	CONCLUSIONS: This study indicates that tetrahydrocurcumin protects neurons from TBI-induced apoptotic neuronal death, which may be through modulation autophagy and PI3K/AKT pathways.	tetrahydrocurcumin	39-57	AKT serine/threonine kinase 1	Rattus norvegicus	169-172
28386319-9	2017	We demonstrated that treatment with THC increased expression of autophagy-associated proteins LC3-II and Beclin-1 at 24 h post-TBI.	tetrahydrocurcumin	36-39	beclin 1	Rattus norvegicus	105-113
28386319-12	2017	Treatment with 3-methyladenine (3-MA) mitigated autophagy activation and reversed the inhibitory effect of THC on the translocation of Bax to the mitochondrial membrane.	tetrahydrocurcumin	107-110	BCL2 associated X, apoptosis regulator	Rattus norvegicus	135-138
27748926-0	2016	Suppression of GRASP65 phosphorylation by tetrahydrocurcumin protects against cerebral ischemia/reperfusion injury via ERK signaling.	tetrahydrocurcumin	42-60	golgi reassembly stacking protein 1	Mus musculus	15-22
27748926-0	2016	Suppression of GRASP65 phosphorylation by tetrahydrocurcumin protects against cerebral ischemia/reperfusion injury via ERK signaling.	tetrahydrocurcumin	42-60	mitogen-activated protein kinase 1	Mus musculus	119-122
27748926-7	2016	THC induced a dose-dependent decrease in the phosphorylation of ERK and GRASP65.	tetrahydrocurcumin	0-3	golgi reassembly stacking protein 1	Mus musculus	72-79
27748926-8	2016	Thus, THC attenuated I/R injury-induced activation of the ERK signaling pathway and reduced the phosphorylation of GRASP65.	tetrahydrocurcumin	6-9	mitogen-activated protein kinase 1	Mus musculus	58-61
27748926-8	2016	Thus, THC attenuated I/R injury-induced activation of the ERK signaling pathway and reduced the phosphorylation of GRASP65.	tetrahydrocurcumin	6-9	golgi reassembly stacking protein 1	Mus musculus	115-122
27748926-9	2016	THC exhibited a dose-dependent protective effect against cerebral I/R injury, mediated by suppression of the ERK signaling pathway and a subsequent reduction in GRASP65 phosphorylation.	tetrahydrocurcumin	0-3	mitogen-activated protein kinase 1	Mus musculus	109-112
27748926-9	2016	THC exhibited a dose-dependent protective effect against cerebral I/R injury, mediated by suppression of the ERK signaling pathway and a subsequent reduction in GRASP65 phosphorylation.	tetrahydrocurcumin	0-3	golgi reassembly stacking protein 1	Mus musculus	161-168
29916670-12	2016	VEGF, COX-2, and EGFR were up-regulated in CaSki + vehicle group; however, they were attenuated by THC, celecoxib, and the combination treatments.	tetrahydrocurcumin	99-102	vascular endothelial growth factor A	Mus musculus	0-4
29916670-13	2016	Conclusion: The combinational treatment effect of THC and celecoxib causing inhibition of tumor growth and tumorangiogenesis via down-regulation of VEGF, COX-2 and EGFR expression.	tetrahydrocurcumin	50-53	vascular endothelial growth factor A	Mus musculus	148-152
29916670-13	2016	Conclusion: The combinational treatment effect of THC and celecoxib causing inhibition of tumor growth and tumorangiogenesis via down-regulation of VEGF, COX-2 and EGFR expression.	tetrahydrocurcumin	50-53	prostaglandin-endoperoxide synthase 2	Mus musculus	154-159
29916670-13	2016	Conclusion: The combinational treatment effect of THC and celecoxib causing inhibition of tumor growth and tumorangiogenesis via down-regulation of VEGF, COX-2 and EGFR expression.	tetrahydrocurcumin	50-53	epidermal growth factor receptor	Mus musculus	164-168
26102010-11	2015	However, drug interactions due to the use of THC as an alternative supplement are of concern, particularly in the combinations that include a drug that is a substrate of Cyp1a1, Cyp2b9, and Cyp3a11.	tetrahydrocurcumin	45-48	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	170-176
26899573-5	2016	Meanwhile, cytochrome C was released to cytosol and the loss of mitochondria membrane potential (Deltapsim) was observed after THC treatment.	tetrahydrocurcumin	127-130	cytochrome c, somatic	Homo sapiens	11-23
26881213-9	2016	The CaSki + vehicle group also showed significantly increased COX-2, EGFR, p-ERK1&2, and p-AKT; however they were attenuated by all treatments with THC.	tetrahydrocurcumin	152-155	epidermal growth factor receptor	Mus musculus	69-73
26881213-9	2016	The CaSki + vehicle group also showed significantly increased COX-2, EGFR, p-ERK1&2, and p-AKT; however they were attenuated by all treatments with THC.	tetrahydrocurcumin	152-155	mitogen-activated protein kinase 3	Mus musculus	77-81
26102010-11	2015	However, drug interactions due to the use of THC as an alternative supplement are of concern, particularly in the combinations that include a drug that is a substrate of Cyp1a1, Cyp2b9, and Cyp3a11.	tetrahydrocurcumin	45-48	cytochrome P450, family 2, subfamily b, polypeptide 9	Mus musculus	178-184
26102010-11	2015	However, drug interactions due to the use of THC as an alternative supplement are of concern, particularly in the combinations that include a drug that is a substrate of Cyp1a1, Cyp2b9, and Cyp3a11.	tetrahydrocurcumin	45-48	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	190-197
25502175-3	2015	In addition, curcumin and tetrahydrocurcumin significantly inhibited the release of prominent cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6); however, hexahydrocurcumin and octahydrocurcumin did not significantly alter cytokine release.	tetrahydrocurcumin	26-44	tumor necrosis factor	Mus musculus	115-142
25502175-3	2015	In addition, curcumin and tetrahydrocurcumin significantly inhibited the release of prominent cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6); however, hexahydrocurcumin and octahydrocurcumin did not significantly alter cytokine release.	tetrahydrocurcumin	26-44	tumor necrosis factor	Mus musculus	144-153
25502175-3	2015	In addition, curcumin and tetrahydrocurcumin significantly inhibited the release of prominent cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6); however, hexahydrocurcumin and octahydrocurcumin did not significantly alter cytokine release.	tetrahydrocurcumin	26-44	interleukin 6	Mus musculus	159-172
25502175-3	2015	In addition, curcumin and tetrahydrocurcumin significantly inhibited the release of prominent cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6); however, hexahydrocurcumin and octahydrocurcumin did not significantly alter cytokine release.	tetrahydrocurcumin	26-44	interleukin 6	Mus musculus	174-178
25547723-6	2014	Other studies, however, suggest that THC is superior to curcumin for induction of GSH peroxidase, glutathione-S-transferase, NADPH: quinone reductase, and quenching of free radicals.	tetrahydrocurcumin	37-40	glutathione S-transferase kappa 1	Homo sapiens	98-123
25719941-8	2015	Moreover, tetrahydrocurcumin exhibited protective effects against cisplatin-induced oxidative renal damage in rats by inhibiting cyclooxygenase-2 and caspase-3 activation.	tetrahydrocurcumin	10-28	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	129-145
25719941-8	2015	Moreover, tetrahydrocurcumin exhibited protective effects against cisplatin-induced oxidative renal damage in rats by inhibiting cyclooxygenase-2 and caspase-3 activation.	tetrahydrocurcumin	10-28	caspase 3	Rattus norvegicus	150-159
25789317-9	2015	The CaSki + vehicle group also showed significantly increased VEGF, VEGFR-2, and HIF-1alpha expressions, but they were downregulated when mice were treated with THC at all doses.	tetrahydrocurcumin	161-164	kinase insert domain protein receptor	Mus musculus	68-75
25789317-9	2015	The CaSki + vehicle group also showed significantly increased VEGF, VEGFR-2, and HIF-1alpha expressions, but they were downregulated when mice were treated with THC at all doses.	tetrahydrocurcumin	161-164	hypoxia inducible factor 1, alpha subunit	Mus musculus	81-91
25547723-6	2014	Other studies, however, suggest that THC is superior to curcumin for induction of GSH peroxidase, glutathione-S-transferase, NADPH: quinone reductase, and quenching of free radicals.	tetrahydrocurcumin	37-40	crystallin zeta	Homo sapiens	125-149
25502771-7	2014	Supplementation with THU significantly decreased blood pressure, improved vascular responsiveness, and reversed the structural and mechanical alterations of the aortas, including collagen and elastin deposition.	tetrahydrocurcumin	21-24	elastin	Mus musculus	192-199
24725345-2	2014	In the present study, we hypothesised that the different cellular uptake and/or metabolism of CUR and THC might be a possible explanation for the previously observed differences in their effects on lipid accumulation in THP-1 monocytes/macrophages.	tetrahydrocurcumin	102-105	GLI family zinc finger 2	Homo sapiens	220-225
24725345-6	2014	From these results, it is possible to deduce that CUR and THC are taken up and metabolised differently in THP-1 cells, which determine their biological activity.	tetrahydrocurcumin	58-61	GLI family zinc finger 2	Homo sapiens	106-111
23325575-8	2013	In addition, THC extended lifespan in Drosophila and inhibited the oxidative stress response by regulating FOXO and Sir2.	tetrahydrocurcumin	13-16	forkhead box, sub-group O	Drosophila melanogaster	107-111
24593988-0	2014	Tetrahydrocurcumin induces G2/M cell cycle arrest and apoptosis involving p38 MAPK activation in human breast cancer cells.	tetrahydrocurcumin	0-18	mitogen-activated protein kinase 14	Homo sapiens	74-77
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	43-46	BCL2 associated X, apoptosis regulator	Homo sapiens	192-195
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	43-46	BCL2 apoptosis regulator	Homo sapiens	211-216
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	43-46	caspase 3	Homo sapiens	234-243
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	43-46	H3 histone pseudogene 16	Homo sapiens	266-269
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	43-46	mitogen-activated protein kinase 14	Homo sapiens	296-299
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	mitogen-activated protein kinase 14	Homo sapiens	51-54
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	BCL2 associated X, apoptosis regulator	Homo sapiens	192-195
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	BCL2 apoptosis regulator	Homo sapiens	211-216
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	caspase 3	Homo sapiens	234-243
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	H3 histone pseudogene 16	Homo sapiens	266-269
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	mitogen-activated protein kinase 14	Homo sapiens	296-299
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	mitogen-activated protein kinase 14	Homo sapiens	51-54
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	BCL2 associated X, apoptosis regulator	Homo sapiens	192-195
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	BCL2 apoptosis regulator	Homo sapiens	211-216
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	caspase 3	Homo sapiens	234-243
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	H3 histone pseudogene 16	Homo sapiens	266-269
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	tetrahydrocurcumin	179-182	mitogen-activated protein kinase 14	Homo sapiens	296-299
23325575-8	2013	In addition, THC extended lifespan in Drosophila and inhibited the oxidative stress response by regulating FOXO and Sir2.	tetrahydrocurcumin	13-16	Sirtuin 1	Drosophila melanogaster	116-120
22212488-17	2012	THC also decreased oxidative damage and ameliorated the homocysteinylation of cyto-c in-part by MMP-9 activation which leads to autophagy in I/R groups as compared to sham-operated groups.	tetrahydrocurcumin	0-3	matrix metallopeptidase 9	Mus musculus	96-101
23058916-7	2012	Tetrahydrocurcumin, a curcumin metabolite, showed a less potent inhibitory effect on I(CRAC), and this effect was abolished in C195S Orai1.	tetrahydrocurcumin	0-18	ORAI calcium release-activated calcium modulator 1	Homo sapiens	133-138
21887819-5	2011	At the molecular level, results from Western blot analysis and immunohistochemistry staining showed that dietary CUR and THC exhibited anti-inflammatory activity by decreasing the levels of inducible NOS and COX-2 through downregulation of ERK1/2 activation.	tetrahydrocurcumin	121-124	cytochrome c oxidase II, mitochondrial	Mus musculus	208-213
21887819-5	2011	At the molecular level, results from Western blot analysis and immunohistochemistry staining showed that dietary CUR and THC exhibited anti-inflammatory activity by decreasing the levels of inducible NOS and COX-2 through downregulation of ERK1/2 activation.	tetrahydrocurcumin	121-124	mitogen-activated protein kinase 3	Mus musculus	240-246
21887819-6	2011	In addition, both dietary CUR and THC significantly decreased AOM-induced Wnt-1 and beta-catenin protein expression, as well as the phosphorylation of GSK-3beta in colonic tissue.	tetrahydrocurcumin	34-37	wingless-type MMTV integration site family, member 1	Mus musculus	74-79
21887819-6	2011	In addition, both dietary CUR and THC significantly decreased AOM-induced Wnt-1 and beta-catenin protein expression, as well as the phosphorylation of GSK-3beta in colonic tissue.	tetrahydrocurcumin	34-37	catenin (cadherin associated protein), beta 1	Mus musculus	84-96
21887819-6	2011	In addition, both dietary CUR and THC significantly decreased AOM-induced Wnt-1 and beta-catenin protein expression, as well as the phosphorylation of GSK-3beta in colonic tissue.	tetrahydrocurcumin	34-37	glycogen synthase kinase 3 beta	Mus musculus	151-160
21887819-7	2011	Moreover, dietary feeding with CUR and THC markedly reduced the protein level of connexin-43, an important molecule of gap junctions, indicating that both CUR and THC might interfer with the intercellular communication of crypt cells.	tetrahydrocurcumin	39-42	gap junction protein, alpha 1	Mus musculus	81-92
21887819-7	2011	Moreover, dietary feeding with CUR and THC markedly reduced the protein level of connexin-43, an important molecule of gap junctions, indicating that both CUR and THC might interfer with the intercellular communication of crypt cells.	tetrahydrocurcumin	163-166	gap junction protein, alpha 1	Mus musculus	81-92
22156377-0	2011	Tetrahydrocurcumin extends life span and inhibits the oxidative stress response by regulating the FOXO forkhead transcription factor.	tetrahydrocurcumin	0-18	forkhead box, sub-group O	Drosophila melanogaster	98-102
22156377-4	2011	Here, we show that tetrahydrocurcumin (THC), a curcumin metabolite, regulates the oxidative stress response and aging via FOXO.	tetrahydrocurcumin	19-37	forkhead box, sub-group O	Drosophila melanogaster	122-126
22156377-4	2011	Here, we show that tetrahydrocurcumin (THC), a curcumin metabolite, regulates the oxidative stress response and aging via FOXO.	tetrahydrocurcumin	39-42	forkhead box, sub-group O	Drosophila melanogaster	122-126
22156377-5	2011	In NIH3T3 cells, THC induced nuclear accumulation of FOXO4, a member of the FOXO family of transcription factors, by inhibiting phosphorylation of protein kinase B (PKB)/Akt.	tetrahydrocurcumin	17-20	forkhead box O4	Mus musculus	53-58
22156377-5	2011	In NIH3T3 cells, THC induced nuclear accumulation of FOXO4, a member of the FOXO family of transcription factors, by inhibiting phosphorylation of protein kinase B (PKB)/Akt.	tetrahydrocurcumin	17-20	forkhead box, sub-group O	Drosophila melanogaster	53-57
22156377-5	2011	In NIH3T3 cells, THC induced nuclear accumulation of FOXO4, a member of the FOXO family of transcription factors, by inhibiting phosphorylation of protein kinase B (PKB)/Akt.	tetrahydrocurcumin	17-20	thymoma viral proto-oncogene 1	Mus musculus	165-168
22156377-5	2011	In NIH3T3 cells, THC induced nuclear accumulation of FOXO4, a member of the FOXO family of transcription factors, by inhibiting phosphorylation of protein kinase B (PKB)/Akt.	tetrahydrocurcumin	17-20	thymoma viral proto-oncogene 1	Mus musculus	170-173
22156377-6	2011	In Drosophila melanogaster, THC attenuated the oxidative stress response, an effect that was blocked in a foxo mutant background.	tetrahydrocurcumin	28-31	forkhead box, sub-group O	Drosophila melanogaster	106-110
22156377-8	2011	Based on these results, THC may regulate the aging process via an evolutionarily conserved signaling pathway that includes both foxo and Sir2.	tetrahydrocurcumin	24-27	forkhead box, sub-group O	Drosophila melanogaster	128-132
22156377-8	2011	Based on these results, THC may regulate the aging process via an evolutionarily conserved signaling pathway that includes both foxo and Sir2.	tetrahydrocurcumin	24-27	Sirtuin 1	Drosophila melanogaster	137-141
21928294-0	2011	Tetrahydrocurcumin, a major metabolite of curcumin, induced autophagic cell death through coordinative modulation of PI3K/Akt-mTOR and MAPK signaling pathways in human leukemia HL-60 cells.	tetrahydrocurcumin	0-18	AKT serine/threonine kinase 1	Homo sapiens	122-125
21928294-0	2011	Tetrahydrocurcumin, a major metabolite of curcumin, induced autophagic cell death through coordinative modulation of PI3K/Akt-mTOR and MAPK signaling pathways in human leukemia HL-60 cells.	tetrahydrocurcumin	0-18	mechanistic target of rapamycin kinase	Homo sapiens	126-130
21928294-6	2011	At the molecular levels, the results from Western blot analysis showed that THC significantly down-regulated phosphatidylinositol 3-kinase/protein kinase B and mitogen-activated protein kinase signalings including decreasing the phosphorylation of mammalian target of rapamycin, glycogen synthase kinase 3beta and p70 ribosomal protein S6 kinase.	tetrahydrocurcumin	76-79	protein tyrosine kinase 2 beta	Homo sapiens	139-155
20456495-5	2010	Primary human keratinocytes treated with curcumin or THC demonstrated decreased activation of p44/42 MAP kinases but increased levels of activated p38 MAP kinases.	tetrahydrocurcumin	53-56	interferon induced protein 44	Homo sapiens	94-97
21928294-6	2011	At the molecular levels, the results from Western blot analysis showed that THC significantly down-regulated phosphatidylinositol 3-kinase/protein kinase B and mitogen-activated protein kinase signalings including decreasing the phosphorylation of mammalian target of rapamycin, glycogen synthase kinase 3beta and p70 ribosomal protein S6 kinase.	tetrahydrocurcumin	76-79	mechanistic target of rapamycin kinase	Homo sapiens	248-277
21928294-6	2011	At the molecular levels, the results from Western blot analysis showed that THC significantly down-regulated phosphatidylinositol 3-kinase/protein kinase B and mitogen-activated protein kinase signalings including decreasing the phosphorylation of mammalian target of rapamycin, glycogen synthase kinase 3beta and p70 ribosomal protein S6 kinase.	tetrahydrocurcumin	76-79	glycogen synthase kinase 3 beta	Homo sapiens	279-309
20934924-1	2010	Curcumin and tetrahydrocurcumin (THC) have been found as potent DNMT1 inhibitors, but they suffer from low oral bioavailability and rapid metabolism in vivo.	tetrahydrocurcumin	13-31	DNA methyltransferase (cytosine-5) 1	Mus musculus	64-69
20934924-1	2010	Curcumin and tetrahydrocurcumin (THC) have been found as potent DNMT1 inhibitors, but they suffer from low oral bioavailability and rapid metabolism in vivo.	tetrahydrocurcumin	33-36	DNA methyltransferase (cytosine-5) 1	Mus musculus	64-69
20456495-5	2010	Primary human keratinocytes treated with curcumin or THC demonstrated decreased activation of p44/42 MAP kinases but increased levels of activated p38 MAP kinases.	tetrahydrocurcumin	53-56	mitogen-activated protein kinase 14	Homo sapiens	147-150
20456495-9	2010	Both curcuminoids induced G2/M block and inhibited keratinocyte growth, and THC increased cellular levels of p21, a known p53 transcriptional target.	tetrahydrocurcumin	76-79	H3 histone pseudogene 16	Homo sapiens	109-112
20456495-9	2010	Both curcuminoids induced G2/M block and inhibited keratinocyte growth, and THC increased cellular levels of p21, a known p53 transcriptional target.	tetrahydrocurcumin	76-79	tumor protein p53	Homo sapiens	122-125
17603281-2	2007	In the present study, we investigated whether the phytochemical curcumin and its metabolite tetrahydrocurcumin could induce HO-1 expression and growth inhibition in rat VSMCs and, if so, whether their antiproliferative effect could be mediated via HO-1 expression.	tetrahydrocurcumin	92-110	heme oxygenase 1	Rattus norvegicus	124-128
18565284-0	2008	Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA.	tetrahydrocurcumin	0-18	matrix metallopeptidase 2	Homo sapiens	85-89
18565284-0	2008	Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA.	tetrahydrocurcumin	0-18	plasminogen activator, urokinase	Homo sapiens	94-97
18417733-4	2008	In both the acute (LPS) and chronic inflammation (Tg2576), TC and curcumin similarly reduced interleukin-1beta.	tetrahydrocurcumin	59-61	interleukin 1 beta	Mus musculus	93-110
18417733-6	2008	TC had no impact on plaques or insoluble Abeta, but both reduced Tris-buffered saline-soluble Abeta and phospho-c-Jun NH(2)-terminal kinase (JNK).	tetrahydrocurcumin	0-2	amyloid beta (A4) precursor protein	Mus musculus	94-99
18417733-6	2008	TC had no impact on plaques or insoluble Abeta, but both reduced Tris-buffered saline-soluble Abeta and phospho-c-Jun NH(2)-terminal kinase (JNK).	tetrahydrocurcumin	0-2	mitogen-activated protein kinase 8	Mus musculus	104-139
18417733-6	2008	TC had no impact on plaques or insoluble Abeta, but both reduced Tris-buffered saline-soluble Abeta and phospho-c-Jun NH(2)-terminal kinase (JNK).	tetrahydrocurcumin	0-2	mitogen-activated protein kinase 8	Mus musculus	141-144
18417733-10	2008	Nevertheless, TC did reduce neuroinflammation and soluble Abeta, effects that may be attributable to limiting JNK-mediated transcription.	tetrahydrocurcumin	14-16	amyloid beta (A4) precursor protein	Mus musculus	58-63
18417733-10	2008	Nevertheless, TC did reduce neuroinflammation and soluble Abeta, effects that may be attributable to limiting JNK-mediated transcription.	tetrahydrocurcumin	14-16	mitogen-activated protein kinase 8	Mus musculus	110-113
18408903-0	2008	Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson"s disease induced by MPTP neurodegeneration in mice.	tetrahydrocurcumin	92-110	monoamine oxidase B	Mus musculus	14-33
18408903-6	2008	The results showed that curcumin and tetrahydrocurcumin reversed the MPTP induced depletion of DA and DOPAC which may in part be due to inhibition of MAO-B activity.	tetrahydrocurcumin	37-55	monoamine oxidase B	Mus musculus	150-155
18376071-0	2008	Effect of tetrahydrocurcumin on insulin receptor status in type 2 diabetic rats: studies on insulin binding to erythrocytes.	tetrahydrocurcumin	10-28	insulin receptor	Rattus norvegicus	32-48
18565284-7	2008	Zymography assay was used to analyze the effect of THC on matrix metalloproteinase (MMP)-2, MMP-9, and urokinase plasminogen activator (uPA) secretion from HT1080 cells.	tetrahydrocurcumin	51-54	matrix metallopeptidase 2	Homo sapiens	58-90
18565284-11	2008	Analysis by zymography demonstrated that treatment with THC reduced the levels of MMP-2, MMP-9, and uPA.	tetrahydrocurcumin	56-59	matrix metallopeptidase 2	Homo sapiens	82-87
18565284-11	2008	Analysis by zymography demonstrated that treatment with THC reduced the levels of MMP-2, MMP-9, and uPA.	tetrahydrocurcumin	56-59	matrix metallopeptidase 9	Homo sapiens	89-94
18565284-11	2008	Analysis by zymography demonstrated that treatment with THC reduced the levels of MMP-2, MMP-9, and uPA.	tetrahydrocurcumin	56-59	plasminogen activator, urokinase	Homo sapiens	100-103
18565284-12	2008	THC also inhibited the levels of MT1-MMP and TIMP-2 proteins detected by Western blot analysis.	tetrahydrocurcumin	0-3	matrix metallopeptidase 14	Homo sapiens	33-40
18565284-12	2008	THC also inhibited the levels of MT1-MMP and TIMP-2 proteins detected by Western blot analysis.	tetrahydrocurcumin	0-3	TIMP metallopeptidase inhibitor 2	Homo sapiens	45-51
16960658-4	2007	In this study, the effect of tetrahydrocurcumin (THC) on three ABC drug transporter proteins, P-glycoprotein (P-gp or ABCB1), mitoxantrone resistance protein (MXR or ABCG2) and multidrug resistance protein 1 (MRP1 or ABCC1) was investigated, to assess whether an ultimate metabolite form of curcuminoids (THC) is able to modulate MDR in cancer cells.	tetrahydrocurcumin	49-52	ATP binding cassette subfamily B member 1	Homo sapiens	94-108
17651069-4	2007	In addition, THC caused significant increases in the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione S-transferase, and reduced glutathione in the brains of diabetic rats with significant decrease in the lipid peroxidative markers thiobarbituric acid-reactive substances and hydroperoxides in brain, suggesting efficacy for protection against lipid peroxidation-induced membrane damage.	tetrahydrocurcumin	13-16	catalase	Rattus norvegicus	89-97
17651069-4	2007	In addition, THC caused significant increases in the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione S-transferase, and reduced glutathione in the brains of diabetic rats with significant decrease in the lipid peroxidative markers thiobarbituric acid-reactive substances and hydroperoxides in brain, suggesting efficacy for protection against lipid peroxidation-induced membrane damage.	tetrahydrocurcumin	13-16	hematopoietic prostaglandin D synthase	Rattus norvegicus	123-148
16960658-15	2007	Similarly with MRP1, the efflux of a fluorescent substrate calcein AM was inhibited effectively by THC thereby the accumulation of calcein was increased in MRP1-HEK 293 and not its parental pcDNA3.1-HEK 293 cells.	tetrahydrocurcumin	99-102	ATP binding cassette subfamily C member 1	Homo sapiens	156-160
16960658-16	2007	The MDR reversing properties of THC on P-gp, MRP1, and MXR were determined by MTT assay.	tetrahydrocurcumin	32-35	phosphoglycolate phosphatase	Homo sapiens	39-43
16960658-0	2007	Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.	tetrahydrocurcumin	165-183	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
16960658-0	2007	Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.	tetrahydrocurcumin	165-183	ATP binding cassette subfamily B member 1	Homo sapiens	71-76
16960658-16	2007	The MDR reversing properties of THC on P-gp, MRP1, and MXR were determined by MTT assay.	tetrahydrocurcumin	32-35	ATP binding cassette subfamily C member 1	Homo sapiens	45-49
16960658-6	2007	We report here for the first time that THC is able to inhibit the function of P-gp, MXR and MRP1.	tetrahydrocurcumin	39-42	phosphoglycolate phosphatase	Homo sapiens	78-82
16960658-16	2007	The MDR reversing properties of THC on P-gp, MRP1, and MXR were determined by MTT assay.	tetrahydrocurcumin	32-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	55-58
16960658-0	2007	Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.	tetrahydrocurcumin	165-183	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	112-117
16960658-0	2007	Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.	tetrahydrocurcumin	165-183	ATP binding cassette subfamily B member 1	Homo sapiens	123-153
16960658-0	2007	Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.	tetrahydrocurcumin	165-183	ATP binding cassette subfamily C member 1	Homo sapiens	155-160
16960658-4	2007	In this study, the effect of tetrahydrocurcumin (THC) on three ABC drug transporter proteins, P-glycoprotein (P-gp or ABCB1), mitoxantrone resistance protein (MXR or ABCG2) and multidrug resistance protein 1 (MRP1 or ABCC1) was investigated, to assess whether an ultimate metabolite form of curcuminoids (THC) is able to modulate MDR in cancer cells.	tetrahydrocurcumin	29-47	ATP binding cassette subfamily B member 1	Homo sapiens	94-108
16960658-17	2007	THC significantly increased the sensitivity of vinblastine, mitoxantrone and etoposide in drug resistance KB-V-1, MCF7AdrVp3000 and MRP1-HEK 293 cells, respectively.	tetrahydrocurcumin	0-3	ATP binding cassette subfamily C member 1	Homo sapiens	132-136
16960658-19	2007	Taken together, this study clearly showed that THC inhibits the efflux function of P-gp, MXR and MRP1 and it is able to extend the MDR reversing activity of curcuminoids in vivo.	tetrahydrocurcumin	47-50	phosphoglycolate phosphatase	Homo sapiens	83-87
16960658-19	2007	Taken together, this study clearly showed that THC inhibits the efflux function of P-gp, MXR and MRP1 and it is able to extend the MDR reversing activity of curcuminoids in vivo.	tetrahydrocurcumin	47-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	89-92
16960658-19	2007	Taken together, this study clearly showed that THC inhibits the efflux function of P-gp, MXR and MRP1 and it is able to extend the MDR reversing activity of curcuminoids in vivo.	tetrahydrocurcumin	47-50	ATP binding cassette subfamily C member 1	Homo sapiens	97-101
16960658-6	2007	We report here for the first time that THC is able to inhibit the function of P-gp, MXR and MRP1.	tetrahydrocurcumin	39-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	84-87
16960658-6	2007	We report here for the first time that THC is able to inhibit the function of P-gp, MXR and MRP1.	tetrahydrocurcumin	39-42	ATP binding cassette subfamily C member 1	Homo sapiens	92-96
16960658-7	2007	The results of flow cytometry assay indicated that THC is able to inhibit the function of P-gp and thereby significantly increase the accumulation of rhodamine and calcein AM in KB-V-1 cells.	tetrahydrocurcumin	51-54	phosphoglycolate phosphatase	Homo sapiens	90-94
16960658-11	2007	The interaction of THC with the P-gp molecule was clearly indicated by ATPase assay and photoaffinity labeling of P-gp with transport substrate.	tetrahydrocurcumin	19-22	phosphoglycolate phosphatase	Homo sapiens	32-36
16960658-11	2007	The interaction of THC with the P-gp molecule was clearly indicated by ATPase assay and photoaffinity labeling of P-gp with transport substrate.	tetrahydrocurcumin	19-22	dynein axonemal heavy chain 8	Homo sapiens	71-77
16960658-11	2007	The interaction of THC with the P-gp molecule was clearly indicated by ATPase assay and photoaffinity labeling of P-gp with transport substrate.	tetrahydrocurcumin	19-22	phosphoglycolate phosphatase	Homo sapiens	114-118
16960658-12	2007	THC stimulated P-gp ATPase activity and inhibited the incorporation of [(125)I]-iodoarylazidoprazosin (IAAP) into P-gp in a concentration-dependent manner.	tetrahydrocurcumin	0-3	phosphoglycolate phosphatase	Homo sapiens	15-19
16960658-12	2007	THC stimulated P-gp ATPase activity and inhibited the incorporation of [(125)I]-iodoarylazidoprazosin (IAAP) into P-gp in a concentration-dependent manner.	tetrahydrocurcumin	0-3	dynein axonemal heavy chain 8	Homo sapiens	20-26
16960658-12	2007	THC stimulated P-gp ATPase activity and inhibited the incorporation of [(125)I]-iodoarylazidoprazosin (IAAP) into P-gp in a concentration-dependent manner.	tetrahydrocurcumin	0-3	phosphoglycolate phosphatase	Homo sapiens	114-118
16960658-13	2007	The binding of [(125)I]-IAAP to MXR was also inhibited by THC suggesting that THC interacted with drug binding site of the transporter.	tetrahydrocurcumin	58-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	32-35
16960658-13	2007	The binding of [(125)I]-IAAP to MXR was also inhibited by THC suggesting that THC interacted with drug binding site of the transporter.	tetrahydrocurcumin	78-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	32-35
16960658-14	2007	THC dose dependently inhibited the efflux of mitoxantrone and pheophorbide A from MXR expressing cells (MCF7AdrVp3000 and MCF7FL1000).	tetrahydrocurcumin	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	82-85
16960658-15	2007	Similarly with MRP1, the efflux of a fluorescent substrate calcein AM was inhibited effectively by THC thereby the accumulation of calcein was increased in MRP1-HEK 293 and not its parental pcDNA3.1-HEK 293 cells.	tetrahydrocurcumin	99-102	ATP binding cassette subfamily C member 1	Homo sapiens	15-19
16806281-4	2006	In addition, THC caused significant increase in the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione-S-transferase, reduced glutathione, vitamin C and vitamin E in liver and kidney of diabetic rats with significant decrease in thiobarbituric acid reactive substances (TBARS) and hydroperoxides formation in liver and kidney, suggesting its role in protection against lipid peroxidation induced membrane damage.	tetrahydrocurcumin	13-16	catalase	Rattus norvegicus	88-96
16806281-4	2006	In addition, THC caused significant increase in the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione-S-transferase, reduced glutathione, vitamin C and vitamin E in liver and kidney of diabetic rats with significant decrease in thiobarbituric acid reactive substances (TBARS) and hydroperoxides formation in liver and kidney, suggesting its role in protection against lipid peroxidation induced membrane damage.	tetrahydrocurcumin	13-16	hematopoietic prostaglandin D synthase	Rattus norvegicus	122-147
15073046-10	2004	Curcumin and THC potently inhibited the activity of human recombinant 5-LOX, showing estimated IC(50) values of 0.7 and 3 micro M, respectively.	tetrahydrocurcumin	13-16	arachidonate 5-lipoxygenase	Homo sapiens	70-75
11077049-2	2000	In this study, we investigated the inhibitory effects of curcumin and its metabolites, tetrahydrocurcumin, hexahydrocurcumin, and octahydrocurcumin, on the induction of NO synthase (NOS) in RAW 264.7 cells activated with lipopolysaccharide (LPS).	tetrahydrocurcumin	87-105	nitric oxide synthase 1, neuronal	Mus musculus	169-180
14511674-6	2003	Co-treatment with isoflavones, curcumin and tetrahydrocurcumin, increased [3H]EGCG accumulation significantly in MDCKII/MRP1 and HT-29 cells.	tetrahydrocurcumin	44-62	ATP binding cassette subfamily C member 1	Canis lupus familiaris	120-124
34187277-0	2021	Tetrahydrocurcumin protects against sepsis-induced acute kidney injury via the SIRT1 pathway.	tetrahydrocurcumin	0-18	sirtuin 1	Mus musculus	79-84
10101144-7	1999	Treatment of the plasma with beta-glucuronidase resulted in a decrease in the concentrations of these two putative conjugates and the concomitant appearance of tetrahydrocurcumin (THC) and curcumin, respectively.	tetrahydrocurcumin	160-178	glucuronidase, beta	Mus musculus	29-47
10101144-7	1999	Treatment of the plasma with beta-glucuronidase resulted in a decrease in the concentrations of these two putative conjugates and the concomitant appearance of tetrahydrocurcumin (THC) and curcumin, respectively.	tetrahydrocurcumin	180-183	glucuronidase, beta	Mus musculus	29-47
34960104-0	2021	Tetrahydrocurcumin Upregulates the Adiponectin-AdipoR Pathway and Improves Insulin Signaling and Pancreatic beta-Cell Function in High-Fat Diet/Streptozotocin-Induced Diabetic Obese Mice.	tetrahydrocurcumin	0-18	adiponectin, C1Q and collagen domain containing	Mus musculus	35-46
34960104-5	2021	THC upregulated UCP-1 in adipose tissue and elevated adiponectin levels in the circulation.	tetrahydrocurcumin	0-3	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	16-21
34960104-5	2021	THC upregulated UCP-1 in adipose tissue and elevated adiponectin levels in the circulation.	tetrahydrocurcumin	0-3	adiponectin, C1Q and collagen domain containing	Mus musculus	53-64
34960104-6	2021	THC upregulated the AdipoR1/R2-APPL1-mediated pathway in the liver and skeletal muscle, which contributes to improved insulin signaling, glucose utilization, and lipid metabolism.	tetrahydrocurcumin	0-3	adiponectin receptor 1	Mus musculus	20-27
34960104-6	2021	THC upregulated the AdipoR1/R2-APPL1-mediated pathway in the liver and skeletal muscle, which contributes to improved insulin signaling, glucose utilization, and lipid metabolism.	tetrahydrocurcumin	0-3	adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1	Mus musculus	31-36
34960104-7	2021	Furthermore, THC treatment significantly (p < 0.05) preserved islet mass, reduced apoptosis, and restored defective insulin expression in the pancreatic beta-cells of diabetic obese mice, which was accompanied by an elevation of AdipoR1 and APPL1.	tetrahydrocurcumin	13-16	adiponectin receptor 1	Mus musculus	229-236
34960104-7	2021	Furthermore, THC treatment significantly (p < 0.05) preserved islet mass, reduced apoptosis, and restored defective insulin expression in the pancreatic beta-cells of diabetic obese mice, which was accompanied by an elevation of AdipoR1 and APPL1.	tetrahydrocurcumin	13-16	adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1	Mus musculus	241-246
34960104-8	2021	These results demonstrated a potential mechanism underlying the beneficial effects of THC against hyperglycemia via the adiponectin-AdipoR pathway, and thus, may lead to a novel therapeutic use for type 2 diabetes.	tetrahydrocurcumin	86-89	adiponectin, C1Q and collagen domain containing	Mus musculus	120-131
34187277-11	2021	Mechanistically, THC remarkably increased the expression of SIRT1, accompanied by decreased expressions of downstream molecules Ac-p65 and Ac-foxo1.	tetrahydrocurcumin	17-20	sirtuin 1	Mus musculus	60-65
34187277-12	2021	Meanwhile, the beneficial effects of THC were clearly abolished by the SIRT1-specific inhibitor EX527.	tetrahydrocurcumin	37-40	sirtuin 1	Mus musculus	71-76
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	sirtuin 1	Mus musculus	133-138
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	forkhead box O1	Mus musculus	209-224
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	catalase	Mus musculus	278-281
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	peroxiredoxin 6 pseudogene 2	Mus musculus	315-318
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	interleukin 1 alpha	Mus musculus	370-378
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	interleukin 1 beta	Mus musculus	380-398
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	interleukin 6	Mus musculus	400-404
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	interleukin 6	Mus musculus	406-419
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	hepatitis A virus cellular receptor 1	Mus musculus	421-426
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	hepatitis A virus cellular receptor 1	Mus musculus	428-452
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	scruffy	Mus musculus	476-479
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	sirtuin 1	Mus musculus	499-504
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	tumor necrosis factor	Mus musculus	590-599
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	tumor necrosis factor	Mus musculus	601-628
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	deoxynucleotidyltransferase, terminal	Mus musculus	637-640
34555398-0	2021	Cardio-protective effect of tetrahydrocurcumin, the primary hydrogenated metabolite of curcumin in vivo and in vitro: Induction of apoptosis and autophagy via PI3K/AKT/mTOR pathways.	tetrahydrocurcumin	28-46	AKT serine/threonine kinase 1	Rattus norvegicus	164-167
34555398-0	2021	Cardio-protective effect of tetrahydrocurcumin, the primary hydrogenated metabolite of curcumin in vivo and in vitro: Induction of apoptosis and autophagy via PI3K/AKT/mTOR pathways.	tetrahydrocurcumin	28-46	mechanistic target of rapamycin kinase	Rattus norvegicus	168-172
34555398-9	2021	THC effectively improved antioxidant activity by increasing SOD and CAT activities and decreasing MDA level.	tetrahydrocurcumin	0-3	catalase	Rattus norvegicus	68-71
34555398-10	2021	THC also enhanced mitochondrial membrane potential, inhibited apoptotic cell death, diminished the Bax/Bcl-2 ratio and cleaved caspase-3 level relative to the H/R model.	tetrahydrocurcumin	0-3	BCL2 associated X, apoptosis regulator	Rattus norvegicus	99-102
34555398-10	2021	THC also enhanced mitochondrial membrane potential, inhibited apoptotic cell death, diminished the Bax/Bcl-2 ratio and cleaved caspase-3 level relative to the H/R model.	tetrahydrocurcumin	0-3	BCL2, apoptosis regulator	Rattus norvegicus	103-108
34555398-10	2021	THC also enhanced mitochondrial membrane potential, inhibited apoptotic cell death, diminished the Bax/Bcl-2 ratio and cleaved caspase-3 level relative to the H/R model.	tetrahydrocurcumin	0-3	caspase 3	Rattus norvegicus	127-136
34555398-11	2021	In addition, THC effectively decreased Beclin1 expression and LC3 II/LC3 I ratio, but increased p62 expression, compared with the H/R model group, and decreased the formation of H/R-induced autophagosomes and autolysosomes.	tetrahydrocurcumin	13-16	beclin 1	Rattus norvegicus	39-46
34555398-11	2021	In addition, THC effectively decreased Beclin1 expression and LC3 II/LC3 I ratio, but increased p62 expression, compared with the H/R model group, and decreased the formation of H/R-induced autophagosomes and autolysosomes.	tetrahydrocurcumin	13-16	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	62-74
34555398-11	2021	In addition, THC effectively decreased Beclin1 expression and LC3 II/LC3 I ratio, but increased p62 expression, compared with the H/R model group, and decreased the formation of H/R-induced autophagosomes and autolysosomes.	tetrahydrocurcumin	13-16	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	96-99
34555398-12	2021	Furthermore, THC promoted the phosphorylation of PI3K/AKT/mTOR and induced the expression of hypoxia-inducible factor 1alpha (HIF-1alpha) after H/R.	tetrahydrocurcumin	13-16	AKT serine/threonine kinase 1	Rattus norvegicus	54-57
34555398-12	2021	Furthermore, THC promoted the phosphorylation of PI3K/AKT/mTOR and induced the expression of hypoxia-inducible factor 1alpha (HIF-1alpha) after H/R.	tetrahydrocurcumin	13-16	mechanistic target of rapamycin kinase	Rattus norvegicus	58-62
34555398-12	2021	Furthermore, THC promoted the phosphorylation of PI3K/AKT/mTOR and induced the expression of hypoxia-inducible factor 1alpha (HIF-1alpha) after H/R.	tetrahydrocurcumin	13-16	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	93-124
34555398-12	2021	Furthermore, THC promoted the phosphorylation of PI3K/AKT/mTOR and induced the expression of hypoxia-inducible factor 1alpha (HIF-1alpha) after H/R.	tetrahydrocurcumin	13-16	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	126-136
34555398-14	2021	In conclusion, THC effectively inhibited H/R-induced autophagy and apoptosis via, at least partially, activating the PI3K/AKT/mTOR pathways.	tetrahydrocurcumin	15-18	AKT serine/threonine kinase 1	Rattus norvegicus	122-125
34555398-14	2021	In conclusion, THC effectively inhibited H/R-induced autophagy and apoptosis via, at least partially, activating the PI3K/AKT/mTOR pathways.	tetrahydrocurcumin	15-18	mechanistic target of rapamycin kinase	Rattus norvegicus	126-130
34116562-7	2021	Both Cur and THC treatment could alter the compositions of the gut microbiota in asthmatic mice, characterized by a significant decrease in the ratio of Firmicutes to Bacteroidetes; Cur or THC supplementation also reduced the relative abundances of pro-inflammatory bacteria, e.g., Proteobacteria, Intestinimonas, Unidentified-Ruminococcaceae, and Lachnospiraceae, in OVA-induced mice.	tetrahydrocurcumin	13-16	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	368-371
34428833-0	2021	Tetrahydrocurcumin Downregulates MAPKs/cPLA2 Signaling and Attenuates Platelet Thromboxane A2 Generation, Granule Secretion, and Thrombus Growth.	tetrahydrocurcumin	0-18	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	39-44
34428833-4	2021	We found that THC significantly attenuated agonist-induced granule secretion in human gel-filtered platelets in vitro, including CD62P and CD63 expression and platelet factor 4, CCL5, and adenosine triphosphate release.	tetrahydrocurcumin	14-17	selectin P	Homo sapiens	129-134
34428833-4	2021	We found that THC significantly attenuated agonist-induced granule secretion in human gel-filtered platelets in vitro, including CD62P and CD63 expression and platelet factor 4, CCL5, and adenosine triphosphate release.	tetrahydrocurcumin	14-17	CD63 molecule	Homo sapiens	139-143
34428833-4	2021	We found that THC significantly attenuated agonist-induced granule secretion in human gel-filtered platelets in vitro, including CD62P and CD63 expression and platelet factor 4, CCL5, and adenosine triphosphate release.	tetrahydrocurcumin	14-17	C-C motif chemokine ligand 5	Homo sapiens	178-182
34428833-5	2021	These inhibitory effects of THC were partially mediated by the attenuation of cytosolic phospholipase A2 (cPLA2) phosphorylation, leading to a decrease in thromboxane A2 (TxA2) generation.	tetrahydrocurcumin	28-31	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	78-104
34428833-5	2021	These inhibitory effects of THC were partially mediated by the attenuation of cytosolic phospholipase A2 (cPLA2) phosphorylation, leading to a decrease in thromboxane A2 (TxA2) generation.	tetrahydrocurcumin	28-31	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	106-111
34428833-6	2021	Moreover, the MAPK (Erk1/2, JNK1/2, and p38 MAPK) signaling pathways were downregulated by THC treatment, resulting in reduced cPLA2 activation, TxA2 generation, and granule secretion.	tetrahydrocurcumin	91-94	mitogen-activated protein kinase 3	Mus musculus	20-26
34428833-6	2021	Moreover, the MAPK (Erk1/2, JNK1/2, and p38 MAPK) signaling pathways were downregulated by THC treatment, resulting in reduced cPLA2 activation, TxA2 generation, and granule secretion.	tetrahydrocurcumin	91-94	mitogen-activated protein kinase 8	Mus musculus	28-34
34428833-6	2021	Moreover, the MAPK (Erk1/2, JNK1/2, and p38 MAPK) signaling pathways were downregulated by THC treatment, resulting in reduced cPLA2 activation, TxA2 generation, and granule secretion.	tetrahydrocurcumin	91-94	mitogen-activated protein kinase 14	Mus musculus	40-48
34428833-6	2021	Moreover, the MAPK (Erk1/2, JNK1/2, and p38 MAPK) signaling pathways were downregulated by THC treatment, resulting in reduced cPLA2 activation, TxA2 generation, and granule secretion.	tetrahydrocurcumin	91-94	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	127-132
34428833-10	2021	Thus, through inhibiting MAPKs/cPLA2 signaling, and attenuating platelet TxA2 generation, granule secretion, and thrombus formation, THC may be a potent cardioprotective agent.	tetrahydrocurcumin	133-136	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	31-36
34679727-8	2021	We observed that THC had similar binding capability and Abeta aggregation inhibition such as keto/enol Cur and it was greater than BDMC and DMC.	tetrahydrocurcumin	17-20	amyloid beta (A4) precursor protein	Mus musculus	56-61
34116562-7	2021	Both Cur and THC treatment could alter the compositions of the gut microbiota in asthmatic mice, characterized by a significant decrease in the ratio of Firmicutes to Bacteroidetes; Cur or THC supplementation also reduced the relative abundances of pro-inflammatory bacteria, e.g., Proteobacteria, Intestinimonas, Unidentified-Ruminococcaceae, and Lachnospiraceae, in OVA-induced mice.	tetrahydrocurcumin	189-192	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	368-371
34452146-4	2021	It was demonstrated that THC could effectively inhibit the alpha-MSH (melanocyte-stimulating hormone) induced melanin production in B16F10 melanoma cells and the expressions of three key enzymes involved with the biosynthetic process of melanin, tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2), were all significantly reduced.	tetrahydrocurcumin	25-28	STAM binding protein	Mus musculus	59-68
34474516-10	2021	CONCLUSION: THU alleviated kidney injury in mice with HFD-induced type 2 diabetes, possibly by blunting the activation of the intrarenal RAS/nicotinamide adenine dinucleotide phosphate oxidase IV (NOX4)/monocyte chemoattractant protein 1 (MCP-1) axis and by lowering the high SBP.	tetrahydrocurcumin	12-15	NADPH oxidase 4	Mus musculus	197-201
34474516-10	2021	CONCLUSION: THU alleviated kidney injury in mice with HFD-induced type 2 diabetes, possibly by blunting the activation of the intrarenal RAS/nicotinamide adenine dinucleotide phosphate oxidase IV (NOX4)/monocyte chemoattractant protein 1 (MCP-1) axis and by lowering the high SBP.	tetrahydrocurcumin	12-15	chemokine (C-C motif) ligand 2	Mus musculus	203-237
34474516-10	2021	CONCLUSION: THU alleviated kidney injury in mice with HFD-induced type 2 diabetes, possibly by blunting the activation of the intrarenal RAS/nicotinamide adenine dinucleotide phosphate oxidase IV (NOX4)/monocyte chemoattractant protein 1 (MCP-1) axis and by lowering the high SBP.	tetrahydrocurcumin	12-15	chemokine (C-C motif) ligand 2	Mus musculus	239-244
34452146-4	2021	It was demonstrated that THC could effectively inhibit the alpha-MSH (melanocyte-stimulating hormone) induced melanin production in B16F10 melanoma cells and the expressions of three key enzymes involved with the biosynthetic process of melanin, tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2), were all significantly reduced.	tetrahydrocurcumin	25-28	dopachrome tautomerase	Mus musculus	306-334
34452146-4	2021	It was demonstrated that THC could effectively inhibit the alpha-MSH (melanocyte-stimulating hormone) induced melanin production in B16F10 melanoma cells and the expressions of three key enzymes involved with the biosynthetic process of melanin, tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2), were all significantly reduced.	tetrahydrocurcumin	25-28	tRNA proline 2	Mus musculus	336-341
34452146-4	2021	It was demonstrated that THC could effectively inhibit the alpha-MSH (melanocyte-stimulating hormone) induced melanin production in B16F10 melanoma cells and the expressions of three key enzymes involved with the biosynthetic process of melanin, tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2), were all significantly reduced.	tetrahydrocurcumin	25-28	tyrosinase	Mus musculus	246-256
34452146-4	2021	It was demonstrated that THC could effectively inhibit the alpha-MSH (melanocyte-stimulating hormone) induced melanin production in B16F10 melanoma cells and the expressions of three key enzymes involved with the biosynthetic process of melanin, tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2), were all significantly reduced.	tetrahydrocurcumin	25-28	tyrosinase	Mus musculus	258-261
34452146-4	2021	It was demonstrated that THC could effectively inhibit the alpha-MSH (melanocyte-stimulating hormone) induced melanin production in B16F10 melanoma cells and the expressions of three key enzymes involved with the biosynthetic process of melanin, tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2), were all significantly reduced.	tetrahydrocurcumin	25-28	tyrosinase-related protein 1	Mus musculus	264-292
34452146-4	2021	It was demonstrated that THC could effectively inhibit the alpha-MSH (melanocyte-stimulating hormone) induced melanin production in B16F10 melanoma cells and the expressions of three key enzymes involved with the biosynthetic process of melanin, tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2), were all significantly reduced.	tetrahydrocurcumin	25-28	tyrosinase-related protein 1	Mus musculus	294-299
34222477-8	2021	THC administration decreased TNF-alpha, Nox2, Nox4, and phosphorylated p65 levels and activated the Nrf2 pathway.	tetrahydrocurcumin	0-3	tumor necrosis factor	Mus musculus	29-38
34222477-8	2021	THC administration decreased TNF-alpha, Nox2, Nox4, and phosphorylated p65 levels and activated the Nrf2 pathway.	tetrahydrocurcumin	0-3	cytochrome b-245, beta polypeptide	Mus musculus	40-44
34222477-8	2021	THC administration decreased TNF-alpha, Nox2, Nox4, and phosphorylated p65 levels and activated the Nrf2 pathway.	tetrahydrocurcumin	0-3	NADPH oxidase 4	Mus musculus	46-50
34222477-8	2021	THC administration decreased TNF-alpha, Nox2, Nox4, and phosphorylated p65 levels and activated the Nrf2 pathway.	tetrahydrocurcumin	0-3	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	71-74
34222477-8	2021	THC administration decreased TNF-alpha, Nox2, Nox4, and phosphorylated p65 levels and activated the Nrf2 pathway.	tetrahydrocurcumin	0-3	nuclear factor, erythroid derived 2, like 2	Mus musculus	100-104
34222477-9	2021	Interestingly, THC administration suppressed the expression of the autophagy markers LC3, Atg5, and Beclin 1.	tetrahydrocurcumin	15-18	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	85-88
34222477-9	2021	Interestingly, THC administration suppressed the expression of the autophagy markers LC3, Atg5, and Beclin 1.	tetrahydrocurcumin	15-18	autophagy related 5	Mus musculus	90-94
34222477-9	2021	Interestingly, THC administration suppressed the expression of the autophagy markers LC3, Atg5, and Beclin 1.	tetrahydrocurcumin	15-18	beclin 1, autophagy related	Mus musculus	100-108
34243602-0	2021	Tetrahydrocurcumin ameliorates Alzheimer"s pathological phenotypes by inhibition of microglial cell cycle arrest and apoptosis via Ras/ERK signaling.	tetrahydrocurcumin	0-18	mitogen-activated protein kinase 1	Mus musculus	135-138
35214966-8	2022	The in vivo pharmacodynamics of THC-SLNs gel in 2,4-dinitrochlorobenzene (DNCB)-induced AD mice showed enhanced bioactivity; reduced levels of TNF-alpha and IL-6; and complete healing, as evident from histopathological studies.	tetrahydrocurcumin	32-35	tumor necrosis factor	Mus musculus	143-152
35214966-8	2022	The in vivo pharmacodynamics of THC-SLNs gel in 2,4-dinitrochlorobenzene (DNCB)-induced AD mice showed enhanced bioactivity; reduced levels of TNF-alpha and IL-6; and complete healing, as evident from histopathological studies.	tetrahydrocurcumin	32-35	interleukin 6	Mus musculus	157-161